<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-842-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SIMPONI 100 mg/ml suspension for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GOLIMUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4966.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAXTER PHARMACEUTICAL SOLUTION LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAXTER PHARMACEUTICAL SOLUTION LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JANSSEN-BIOLOGICS B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AB06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Simponi contains the active substance called golimumab.</p><p>&nbsp;</p><p>Simponi belongs to a group of medicines called &lsquo;TNF blockers&rsquo;. It is used <strong>in adults</strong> for the treatment of the following inflammatory diseases:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rheumatoid arthritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psoriatic arthritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Axial spondyloarthritis, including ankylosing spondylitis and non‑radiographic axial spondyloarthritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ulcerative colitis</p><p>&nbsp;</p><p>Simponi works by blocking the action of a protein called &lsquo;tumour necrosis factor alpha&rsquo; (TNF‑&alpha;). This protein is involved in inflammatory processes of the body, and blocking it can reduce the inflammation in your body.</p><p>&nbsp;</p><p><strong>Rheumatoid arthritis</strong></p><p>Rheumatoid arthritis is an inflammatory disease of the joints. If you have active rheumatoid arthritis</p><p>you will first be given other medicines. If you do not respond well enough to these medicines, you may be given Simponi which you will take in combination with another medicine called methotrexate to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduce the signs and symptoms of your disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow down the damage to your bones and joints.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Improve your physical function.</p><p><strong>&nbsp;</strong></p><p><strong>Psoriatic arthritis</strong></p><p>Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis, an inflammatory disease of the skin. If you have active psoriatic arthritis you will first be given other medicines. If you do not respond well enough to these medicines, you may be given Simponi to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduce the signs and symptoms of your disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow down the damage to your bones and joints.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Improve your physical function.</p><p><strong>&nbsp;</strong></p><p><strong>Ankylosing spondylitis and non</strong>‑<strong>radiographic axial spondyloarthritis</strong></p><p>Ankylosing spondylitis and non‑radiographic axial spondyloarthritis are inflammatory diseases of the spine. If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis, you will first be given other medicines. If you do not respond well enough to these medicines, you may be given Simponi to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduce the signs and symptoms of your disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Improve your physical function.</p><p>&nbsp;</p><p><strong>Ulcerative colitis</strong></p><p>Ulcerative colitis is an inflammatory disease of the bowel. If you have ulcerative colitis you will first</p><p>be given other medicines. If you do not respond well enough to these medicines, you will be given</p><p>Simponi to treat your disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Simponi:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to golimumab or any of the other ingredients of this medicine (listed in Section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have tuberculosis (TB) or any other severe infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have moderate or severe heart failure.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Simponi.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Simponi.</p><p><strong>&nbsp;</strong></p><p><u>Infections</u></p><p>Tell your doctor straight away if you already have or get any symptoms of infection, during or after your treatment with Simponi. Symptoms of infection include fever, cough, shortness of breath, flu‑like symptoms, diarrhoea, wounds, dental problems or a burning feeling when urinating.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may get infections more easily while using Simponi.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections may progress more rapidly and may be more severe. In addition, some previous infections may reappear.</p><p>&nbsp;</p><p><em>Tuberculosis (TB)</em></p><p>Tell your doctor straight away if symptoms of TB appear during or after your treatment. Symptoms of TB include persistent cough, weight loss, tiredness, fever or night sweats.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cases of TB have been reported in patients treated with Simponi, in rare occasions even in patients who have been treated with medicines for TB. Your doctor will test you to see if you have TB. Your doctor will record these tests on your Patient Alert Card.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is very important that you tell your doctor if you have ever had TB, or if you have been in close contact with someone who has had or has TB.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor feels that you are at risk of TB, you may be treated with medicines for TB before you begin using Simponi.</p><p>&nbsp;</p><p><em>Hepatitis B virus (HBV)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you are a carrier or if you have or have had HBV before you are given Simponi.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you think you might be at risk of contracting HBV</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor should test you for HBV</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with TNF blockers such as Simponi may result in reactivation of HBV in patients who carry this virus, which can be life‑threatening in some cases.</p><p>&nbsp;</p><p><em>Invasive fungal infections</em></p><p>If you have lived in or travelled to an area where infections caused by specific type of fungi that can affect the lungs or other parts of the body (called histoplasmosis, coccidioidomycosis, or blastomycosis), are common, tell your doctor straight away. Ask your doctor if you don&rsquo;t know if these fungal infections are common in the area in which you have lived or travelled.</p><p>&nbsp;</p><p><u>Cancer and lymphoma</u></p><p>Tell your doctor if you have ever been diagnosed with lymphoma (a type of blood cancer) or any other cancer before you use Simponi.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you use Simponi or other TNF blockers, your risk for developing lymphoma or another cancer may increase.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with severe rheumatoid arthritis and other inflammatory diseases, who have had the disease for a long time, may be at higher than average risk of developing lymphoma.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been cases of cancers, including unusual types, in children and teenage patients taking TNF‑blocking agents, which sometimes resulted in death.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On rare occasions, a specific and severe type of lymphoma called hepatosplenic T‑cell lymphoma has been observed in patients taking other TNF‑blockers. Most of these patients were adolescent or young adult males. This type of cancer has usually resulted in death. Almost all of these patients had also received medicines known as azathioprine or 6‑mercaptopurine. Tell your doctor if you are taking azathioprine or 6‑mercaptopurine with Simponi.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with severe persistent asthma, chronic obstructive pulmonary disease (COPD), or are heavy smokers may be at increased risk for cancer with Simponi treatment. If you have severe persistent asthma, COPD or are a heavy smoker, you should discuss with your doctor whether treatment with a TNF blocker is appropriate for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some patients treated with golimumab have developed certain kinds of skin cancer. If any changes in the appearance of the skin or growths on the skin occur during or after therapy, tell your doctor.</p><p><strong>&nbsp;</strong></p><p><u>Heart failure</u></p><p>Tell your doctor straight away if you get new or worsening symptoms of heart failure. Symptoms of heart failure include shortness of breath or swelling of your feet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New and worsening congestive heart failure has been reported with TNF blockers, including Simponi. Some of these patients died.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have mild heart failure and you are being treated with Simponi, you must be closely monitored by your doctor.</p><p>&nbsp;</p><p><u>Nervous system disease</u></p><p>Tell your doctor straight away if you have ever been diagnosed with or develop symptoms of a demyelinating disease such as multiple sclerosis. Symptoms may include changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body. Your doctor will decide if you should receive Simponi.</p><p><u>&nbsp;</u></p><p><u>Operations or dental procedures</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor if you are going to have any operations or dental procedures.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your surgeon or dentist performing the procedure that you are having treatment with Simponi by showing them your Patient Alert Card.</p><p>&nbsp;</p><p><u>Autoimmune disease</u></p><p>Tell your doctor if you develop symptoms of a disease called lupus. Symptoms include persistent rash, fever, joint pain and tiredness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On rare occasions, people treated with TNF blockers have developed lupus.</p><p>&nbsp;</p><p><u>Blood disease</u></p><p>In some patients the body may fail to produce enough of the blood cells that help your body fight infections or help you to stop bleeding. If you develop a fever that does not go away, bruise or bleed very easily or look very pale, call your doctor right away. Your doctor may decide to stop treatment.</p><p><strong>&nbsp;</strong></p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Simponi.</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p>Talk to your doctor if you have had, or are due to have a vaccine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not receive certain (live) vaccines while using Simponi.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain vaccinations may cause infections. If you received Simponi while you were pregnant, your baby may be at higher risk for getting such an infection for up to approximately six months after the last dose you received during pregnancy. It is important that you tell your baby&#39;s doctors and other health care professionals about your Simponi use so they can decide when your baby should receive any vaccine.</p><p>&nbsp;</p><p><u>Therapeutic infectious agents</u></p><p>Talk to your doctor if you have recently received or are scheduled to receive treatment with a therapeutic infectious agent (such as BCG instillation used for the treatment of cancer).</p><p>&nbsp;</p><p><u>Allergic reactions</u></p><p>Tell your doctor straight away if you develop symptoms of an allergic reaction after your treatment with Simponi. Symptoms of an allergic reaction may include swelling of the face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some of these reactions may be serious or, rarely, life‑threatening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some of these reactions occurred after the first administration of Simponi.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Simponi 100&nbsp;mg is not recommended for children and adolescents (younger than 18&nbsp;years).</p><p>&nbsp;</p><p><strong>Other medicines and Simponi</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines, including any other medicines to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non‑radiographic axial spondyloarthritis, or ulcerative colitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not take Simponi with medicines containing the active substance anakinra or abatacept. These medicines are used for the treatment of rheumatic diseases.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor or pharmacist if you are taking any other medicines that affect your immune system.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not receive certain (live) vaccines while using Simponi.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Simponi.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding</strong></p><p>Talk to your doctor before using Simponi if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are pregnant or are planning to become pregnant while using Simponi. The effects of this medicine in pregnant women are not known. The use of Simponi in pregnant women is not recommended. If you are being treated with Simponi, you must avoid becoming pregnant by using adequate contraception during your treatment and for at least 6&nbsp;months after the last Simponi injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before starting breast‑feeding, your last treatment with Simponi must be at least 6&nbsp;months ago. You must stop breast‑feeding if you are to be given Simponi.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you received Simponi during your pregnancy, your baby may have a higher risk for getting an infection. It is important that you tell your baby&rsquo;s doctors and other health care professionals about your Simponi use before the baby receives any vaccine (for more information see section on vaccination).</p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Simponi may have a minor influence on your ability to drive and use tools or machines. Dizziness may occur after you take Simponi. If this happens, do not drive or use any tools or machines.</p><p>&nbsp;</p><p><strong>Simponi contains latex and sorbitol</strong></p><p><u>Latex sensitivity</u></p><p>A part of the pre‑filled syringe, the needle cover, contains latex. Because latex may cause severe allergic reactions, talk to your doctor before using Simponi if you or your carer are allergic to latex.</p><p>&nbsp;</p><p><u>Sorbitol intolerance</u></p><p>Simponi contains sorbitol (E420). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much Simponi is given</strong></p><p>Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 50&nbsp;mg given once a month, on the same date each month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor before taking your fourth dose. Your doctor will determine if you should continue Simponi treatment.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you weigh more than 100&nbsp;kg, the dose might be increased to 100&nbsp;mg (the content of 1&nbsp;pre‑filled syringe) given once a month, on the same date each month.</p><p>&nbsp;</p><p>Ulcerative colitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The table below shows how you will usually use this medicine.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Initial treatment</p></td><td><p>A starting dose of 200&nbsp;mg (the contents of 2&nbsp;pre-filled syringes) followed by 100&nbsp;mg (the contents of 1&nbsp;pre-filled syringe) 2&nbsp;weeks later.</p></td></tr><tr><td><p>Maintenance treatment</p></td><td><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients weighing less than 80&nbsp;kg, 50&nbsp;mg (the 50 mg pre-filled pen or pre-filled syringe must be used to administer this dose) 4&nbsp;weeks after your last treatment, then every 4&nbsp;weeks thereafter.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients weighing 80&nbsp;kg or more, 100&nbsp;mg (the contents of 1&nbsp;pre‑filled syringe) 4&nbsp;weeks after your last treatment, then every 4&nbsp;weeks thereafter.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>How Simponi is given</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Simponi is given by injection under the skin (subcutaneously).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the start, your doctor or nurse may inject Simponi. However, you and your doctor may decide that you may inject Simponi yourself. In this case you will get training on how to inject Simponi yourself.</p><p>Talk to your doctor if you have any questions about giving yourself an injection. You will find detailed &ldquo;Instructions for administration&rdquo; at the end of this leaflet.</p><p><strong>&nbsp;</strong></p><p><strong>If you use more Simponi than you should</strong></p><p>If you have used or been given too much Simponi (either by injecting too much on a single occasion, or by using it too often), talk to your doctor or pharmacist straight away. Always take the outer carton and this leaflet with you, even if it is empty.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to use Simponi</strong></p><p>If you forget to use Simponi on your planned date, inject the forgotten dose as soon as you remember.</p><p>&nbsp;</p><p>Do not use a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>When to inject your next dose:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are less than 2&nbsp;weeks late, inject the forgotten dose as soon as you remember and stay on your original schedule.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are more than 2&nbsp;weeks late, inject the forgotten dose as soon as you remember and talk to your doctor or pharmacist to ask when you need to take the next dose.</p><p>&nbsp;</p><p>If you are not sure what to do, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you stop using Simponi</strong></p><p>If you are considering stopping Simponi, talk to your doctor or pharmacist first.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>&nbsp;</u></p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some patients may experience serious side effects and may require treatment. The risk of certain side effects is greater with the 100&nbsp;mg dose compared with the 50&nbsp;mg dose. Side effects may appear up to several months after the last injection.</p><p>&nbsp;</p><p>Tell your doctor straight away if you notice any of the following serious side effects of Simponi which include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>allergic reactions which may be serious, or rarely, life‑threatening (rare).</strong> Symptoms of an allergic reaction may include swelling of the face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles. Some of these reactions occurred after the first administration of Simponi.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>serious infections (including TB, bacterial infections including serious blood infections and pneumonia, severe fungal infections and other opportunistic infections) (common).</strong> Symptoms of an infection can include fever, tiredness, (persistent) cough, shortness of breath, flu‑like symptoms, weight loss, night sweats, diarrhoea, wounds, dental problems and a burning feeling when urinating.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>reactivation of hepatitis B virus if you are a carrier or have had hepatitis B before (rare).</strong> Symptoms can include yellowing of the skin and eyes, dark brown‑coloured urine, right‑sided abdominal pain, fever, feeling sick, being sick, and feeling very tired.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>nervous system disease such as multiple sclerosis (rare).</strong> Symptoms of nervous system disease can include changes in your vision, weakness in your arms or legs, numbness or tingling in any part of your body.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>cancer of the lymph nodes (lymphoma) (rare).</strong> Symptoms of lymphoma can include swelling of the lymph nodes, weight loss, or fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>heart failure (rare).</strong> Symptoms of heart failure can include shortness of breath or swelling of your feet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>signs of immune system disorders called:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>lupus (rare). </strong>Symptoms can include joint pain or a rash on cheeks or arms that is sensitive to the sun.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>sarcoidosis (rare). </strong>Symptoms can include a persistent cough, being short of breath, chest pain, fever, swelling of your lymph nodes, weight loss, skin rashes, and blurred vision.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>swelling of small blood vessels (vasculitis) (rare). </strong>Symptoms can include fever, headache, weight loss, night sweats, rash, and nerve problems such as numbness and tingling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>skin cancer (uncommon). </strong>Symptoms of skin cancer can include changes in the appearance of your skin or growths on your skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>blood disease (common).</strong> Symptoms of blood disease can include a fever that does not go away, bruising or bleeding very easily or looking very pale.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>blood cancer (leukaemia) (rare)</strong>. Symptoms of leukaemia can include fever, feeling tired, frequent infections, easy bruising, and night sweats.</p><p>Tell your doctor straight away if you notice any of the above symptoms.</p><p>&nbsp;</p><p><strong>The following additional side effects have been observed with Simponi:</strong></p><p><u>Very common side effects (may affect more than 1 in 10&nbsp;people):</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upper respiratory tract infections, sore throat or hoarseness, runny nose</p><p>&nbsp;</p><p><u>Common side effects (</u><u>may affect up to 1 in 10&nbsp;people)</u><u>:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver tests (increased liver enzymes) found during blood tests done by your doctor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling numb or having a tingling feeling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Superficial fungal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abscess</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial infections (such as cellulitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low red blood cell counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Positive blood lupus test</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cold sores</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma, shortness of breath, wheezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach and bowel disorders which include inflammation of the stomach lining and colon which may cause fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain and ulcers in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reactions (including redness, hardness, pain, bruising, itching, tingling and irritation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash and itching of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone fractures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest discomfort</p><p>&nbsp;</p><p><u>Uncommon side effects (</u><u>may affect up to 1 in 100&nbsp;people)</u><u>:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancers, including skin cancer and non‑cancerous growths or lumps, including skin moles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin blisters</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psoriasis (including on the palms of your hand and/or the soles of your feet and/or in the form of skin blisters)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low platelet count</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low white blood cell counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Combined low platelet, red, and white blood cell count</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thyroid disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in blood sugar levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in blood cholesterol levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Balance disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision disturbances</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensation of heart beating irregularly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Narrowing of the blood vessels in the heart</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic inflammatory condition of the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acid reflux</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gall stones</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Menstrual disorders</p><p>&nbsp;</p><p><u>Rare side effects (may affect up to 1 in 1,000&nbsp;people):</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Failure of the bone marrow to produce blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the joints or the tissue around them</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired healing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of blood vessels in internal organs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukaemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Melanoma (a type of skin cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Scaly, peeling skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as sarcoidosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain and discoloration in the fingers or toes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste disturbances</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bladder disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the blood vessels in your skin which results in rash</p><p>&nbsp;</p><p><u>Side effects of which the frequency is not known:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Merkel cell carcinoma (a type of skin cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A rare blood cancer affecting mostly young people (hepatosplenic T-cell lymphoma)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the label and the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&deg;C‑8&deg;C). Do not freeze.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the pre‑filled syringe in the outer carton in order to protect it from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice that the liquid is not a clear to light yellow colour, cloudy, or contains foreign particles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Simponi contains</strong></p><p>The active substance is golimumab. One 1&nbsp;mL pre‑filled syringe contains 100&nbsp;mg of golimumab.</p><p>The other ingredients are sorbitol (E420), L‑histidine, L‑histidine monohydrochloride monohydrate, polysorbate&nbsp;80 and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Simponi looks like and contents of the pack
Simponi is supplied as solution for injection in a single use pre filled syringe Simponi is available in packs containing 1 pre filled syringe and multipacks containing 3 (3 packs of 1) pre filled syringes. Not all pack sizes may be marketed.
	
	The solution is clear to slightly opalescent (having a pearl like shine), colourless to light yellow and may contain a few small translucent or white particles of protein. Do not use Simponi if the solution is discoloured, cloudy or you can see foreign particles in it.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Janssen Biologics&nbsp;B.V.</p><p>Einsteinweg 101</p><p>2333 CB Leiden</p><p>The Netherlands</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Belgi&euml;/Belgique/Belgien</strong></p><p>MSD Belgium BVBA/SPRL</p><p>T&eacute;l/Tel: 0800 38 693 (+32(0)27766211)</p><p>dpoc_belux@merck.com</p><p>&nbsp;</p></td><td><p><strong>Lietuva</strong></p><p>UAB Merck Sharp &amp; Dohme</p><p>Tel. + 370 5 278 02 47</p><p>msd_lietuva@merck.com</p><p>&nbsp;</p></td></tr><tr><td><p><strong>България</strong></p><p>Мерк Шарп и Доум България ЕООД</p><p>Тел.: +359 2 819 3737</p><p>info-msdbg@merck.com</p><p>&nbsp;</p></td><td><p><strong>Luxembourg/Luxemburg</strong></p><p>MSD Belgium BVBA/SPRL</p><p>T&eacute;l/Tel: (+32(0)27766211)</p><p>dpoc_belux@merck.com</p><p>&nbsp;</p></td></tr><tr><td><p><strong>Česk&aacute; republika</strong></p><p>Merck Sharp &amp; Dohme s.r.o.</p><p>Tel: +420 233 010 111</p><p>dpoc_czechslovak@merck.com</p><p>&nbsp;</p></td><td><p><strong>Magyarorsz&aacute;g</strong></p><p>MSD Pharma Hungary Kft.</p><p>Tel.: +36&nbsp;1&nbsp;888&nbsp;5300</p><p>hungary_msd@merck.com</p><p>&nbsp;</p></td></tr><tr><td><p><strong>Danmark</strong></p><p>MSD Danmark ApS</p><p>Tlf: + 45 4482 4000</p><p>dkmail@merck.com</p><p>&nbsp;</p></td><td><p><strong>Malta</strong></p><p>Merck Sharp &amp; Dohme Cyprus Limited</p><p>Tel: 8007 4433 (+356 99917558)</p><p>malta_info@merck.com</p><p>&nbsp;</p></td></tr><tr><td><p><strong>Deutschland</strong></p><p>MSD SHARP &amp; DOHME GMBH</p><p>Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)</p><p>e-mail@msd.de</p><p>&nbsp;</p></td><td><p><strong>Nederland</strong></p><p>Merck Sharp &amp; Dohme BV</p><p>Tel: 0800 9999000</p><p>(+31 23 5153153)</p><p>medicalinfo.nl@merck.com</p><p>&nbsp;</p></td></tr><tr><td><p><strong>Eesti</strong></p><p>Merck Sharp &amp; Dohme O&Uuml;</p><p>Tel.: +372&nbsp;6144 200</p><p>msdeesti@merck.com</p><p>&nbsp;</p></td><td><p><strong>Norge</strong></p><p>MSD (Norge) AS</p><p>Tlf: +47 32 20 73 00</p><p>msdnorge@msd.no</p><p>&nbsp;</p></td></tr><tr><td><p><strong>&Epsilon;&lambda;&lambda;ά&delta;&alpha;</strong></p><p>MSD &Alpha;.&Phi;.&Beta;.&Epsilon;.&Epsilon;.</p><p>&Tau;&eta;&lambda;: +30 210 98 97 300</p><p>dpoc_greece@merck.com</p><p>&nbsp;</p></td><td><p><strong>&Ouml;sterreich</strong></p><p>Merck Sharp &amp; Dohme Ges.m.b.H.</p><p>Tel: +43 (0) 1 26 044</p><p>msd-medizin@merck.com</p><p>&nbsp;</p></td></tr><tr><td><p><strong>Espa&ntilde;a</strong></p><p>Merck Sharp &amp; Dohme de Espa&ntilde;a, S.A.</p><p>Tel: +34 91 321 06 00</p><p>msd_info@merck.com</p><p>&nbsp;</p></td><td><p><strong>Polska</strong></p><p>MSD Polska Sp. z o.o.</p><p>Tel: +48 22 549 51 00</p><p>msdpolska@merck.com</p><p>&nbsp;</p></td></tr><tr><td>&nbsp;<p><strong>France</strong></p><p>MSD France</p><p>T&eacute;l: + 33 (0) 1 80 46 40 40</p><p><strong>&nbsp;</strong></p></td><td><p><strong>Portugal</strong></p><p>Merck Sharp &amp; Dohme, Lda</p><p>Tel: +351 21 4465700</p><p>clic@merck.com</p><p>&nbsp;</p></td></tr><tr><td><p><strong>Hrvatska</strong></p><p>Merck Sharp &amp; Dohme d.o.o.</p><p>Tel: + 385 1 6611 333</p><p>croatia_info@merck.com</p><p>&nbsp;</p></td><td><p><strong>Rom&acirc;nia</strong></p><p>Merck Sharp &amp; Dohme Romania S.R.L.</p><p>Tel: +40 21 529 29 00</p><p>msdromania@merck.com</p><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>Ireland</strong></p><p>Merck Sharp &amp; Dohme Ireland (Human Health) Limited</p><p>Tel: +353 (0)1 2998700</p><p>medinfo_ireland@merck.com</p><p>&nbsp;</p></td><td><p><strong>Slovenija</strong></p><p>Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.</p><p>Tel: +386 1 5204 201</p><p>msd.slovenia@merck.com</p><p>&nbsp;</p></td></tr><tr><td><p><strong>&Iacute;sland</strong></p><p>Vistor hf.</p><p>S&iacute;mi: + 354 535 7000</p><p><strong>&nbsp;</strong></p></td><td><p><strong>Slovensk&aacute; republika</strong></p><p>Merck Sharp &amp; Dohme, s. r. o.</p><p>Tel: +421 2 58282010</p><p>dpoc_czechslovak@merck.com</p><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>Italia</strong></p><p>MSD Italia S.r.l.</p><p>Tel: +39 06 361911</p><p>medicalinformation.it@merck.com</p><p><strong>&nbsp;</strong></p></td><td><p><strong>Suomi/Finland</strong></p><p>MSD Finland Oy</p><p>Puh/Tel: +358 (0)9 804 650</p><p>info@msd.fi</p><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>&Kappa;ύ&pi;&rho;&omicron;&sigmaf;</strong></p><p>Merck Sharp &amp; Dohme Cyprus Limited</p><p>&Tau;&eta;&lambda;.: 800 00 673 (+357 22866700)</p><p>cyprus_info@merck.com</p><p><strong>&nbsp;</strong></p></td><td><p><strong>Sverige</strong></p><p>Merck Sharp &amp; Dohme (Sweden) AB</p><p>Tel: +46 77 5700488</p><p>medicinskinfo@merck.com</p><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>Latvija</strong></p><p>SIA Merck Sharp &amp; Dohme Latvija</p><p>Tel: + 371 67364224</p><p>msd_lv@merck.com</p><p>&nbsp;</p></td><td><p><strong>United Kingdom</strong></p><p>Merck Sharp &amp; Dohme Limited</p><p>Tel: +44 (0) 1992 467272</p><p>medicalinformationuk@merck.com</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                DEC 2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي سيمبوني على المادة الفعَّالة التي تسُمى جوليموماب.</p><p dir="RTL">ينتمي دواء سيمبوني إلى مجموعة الأدوية التي يُطُلق عليها &quot;مثبطات TNF&quot;. يُسُتخدم في البالغين لعلاج الأمراض الالتهابية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفصل الروماتويدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الصدفي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الفقارية المحورية، بما في ذلك التهاب الفقار المقسط - والتهاب المفاصل الفقارية المحورية غير الشعاعية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون التقرحي</p><p dir="RTL">يعمل سيمبوني عن طريق إيقاف عمل بروتين يطُلق عليه &quot;عامِلُ نخََرِ الوَرَم ألفا&quot; )TNF-&alpha;(. يكون لهذا البروتين دور في الالتهابات التي يتعرض لها الجسم، وبتثبيطه تقل حدة الالتهابات في جسمك.</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب المفصل الروماتويدي</strong> <strong>&nbsp;</strong></p><p dir="RTL">إن التهاب المفصل الروماتويدي التهاب يصيب المفاصل. إذا كنت تعاني من التهاب المفصل الروماتويدي النشط &nbsp;</p><p dir="RTL">فستوصف لك بعض الأدوية الأخرى أولاً. إذا لم تستجب حالتك استجابة كافية لهذه الأدوية، فسيوصف لك سيمبوني الذي يتعين عليك استخدامه إلى جانب دواء آخر يُسُمى ميثوتريكسات من أجل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحد من علامات المرض وأعراضه لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبطاء تلف العظام والمفاصل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسين الوظائف البدنية لديك.</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الصدفي</strong> <strong>&nbsp;</strong></p><p dir="RTL">التهاب المفاصل الصدفي هو التهاب يصيب المفاصل، وعادة ما يصاحبه داء الصدفية، وهو مرض التهابي يصيب الجلد. إذا كنت تعاني من التهاب المفاصل الصدفي النشط، فستخضع أولاً لبعض الأدوية الأخرى. إذا لم تستجب حالتك استجابة كافية لهذه الأدوية، فسيوصف لك سيمبوني بهدف:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحد من علامات المرض وأعراضه لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبطاء تلف العظام والمفاصل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسين الوظائف البدنية لديك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التهاب الفقار اللاصق </strong>-<strong>والتهاب المفاصل الفقارية المحورية غير الشعاعي</strong>ة<strong> </strong></p><p dir="RTL">التهاب الفقار اللاصق والتهاب المفاصل الفقارية المحورية غير الشعاعية من الالتهابات التي تصيب العمود الفقري. إذا كنت تعاني من التهاب الفقار اللاصق أو التهاب المفاصل الفقارية غير الشعاعية، فستوصف لك بعض الأدوية الأخرى أولاً. إذا لم تستجب حالتك استجابة كافية لهذه الأدوية، فسيوصف لك سيمبوني بهدف:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحد من علامات المرض وأعراضه لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسين الوظائف البدنية لديك.</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب القولون التقرحي</strong> <strong>&nbsp;</strong></p><p dir="RTL">التهاب القولون التقرحي هو التهاب يصيب الأمعاء. إذا كنت تعاني من التهاب القولون التقرحي، فستوصف لك بعض الأدوية الأخرى أولاً.</p><p dir="RTL">إذا لم تستجب حالتك استجابة كافية لهذه الأدوية، فسيوصف لكسيمبوني&nbsp; لعلاج حالتك المرضية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم سيمبوني:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية )فرط الحساسية( تجاه جوليموماب أو أي من المكونات الأخرى في هذا الدواء )المُدرجة بالقسم 6(.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض السل) TB( أو أي عدوى حادة أخرى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حالة سكتة قلبية معتدلة أو حادة.</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا هل تنطبق عليك أي من الحالات المذكورة أعلاه أم لا، فتحدث مع طبيبك أو الصيدلي أو الممرضة المتابعة لحالتك قبل استخدام سيمبوني.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة المتابعة لحالتك قبل استخدام سيمبوني.</p><p><strong>&nbsp;</strong></p><p><u>العداوى</u><strong> </strong></p><p dir="RTL">أخبر طبيبك على الفور إذا كنت تعاني بالفعل من أي أعراض للعدوى، سواء أثناء تلقيك العلاج بدواء سيمبوني أو بعده. تشمل أعراض العدوى الحمى أو السعال أو ضيق التنفس أو أعراض شبيهة بأعراض الأنفلونزا أو الإسهال أو الجروح أو مشاكل الأسنان أو الشعور بالحرقان عند التبول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصُاب بالالتهابات بسهولة أكبر عند استخدام سيمبوني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتطور العدوى بسرعة أكبر وتتحول إلى صورة أكثر حدة. بالإضافة إلى ذلك، فقد تعاود بعض العدوى السابقة الظهور.</p><p>&nbsp;</p><p>مرض السل) <em>TB</em>( <strong>&nbsp;</strong></p><p dir="RTL">أخبر طبيبك على الفور عند ظهور أعراض مرض السل أثناء تلقيك العلاج أو بعده .تشمل أعراض مرض السل السعال المستديم أو فقدان الوزن أو الإجهاد أو الحمى أو التعرق الليلي.</p><p dir="RTL">&bull;&nbsp;&nbsp; تم الإبلاغ عن حالات إصابة بمرض السل في المرضى الذين يتلقون العلاج بدواء سيمبوني في حالات نادرة حتى في المرضى الذين تم علاجهم بالأدوية المخصصة لعلاج مرض السل. سيقوم الطبيب بفحصك لمعرفة إذا كنت مصاباً بمرض السل أم لا. سيسجل طبيبك هذه الاختبارات على بطاقة تنبيه المريض.</p><p dir="RTL">&bull;&nbsp;&nbsp; من المهم جدًا أن تخبر طبيبك إذا كان قد سبق وأصُبت بمرض السل أو إذا كنت قريباً من أحد الأشخاص ممن أصُيب به أو يعاني منه.</p><p dir="RTL">&bull;&nbsp;&nbsp; إذا كان طبيبك يعتقد بأنك عرضة لمخاطر الإصابة بمرض السل، فقد تتلقى العلاج بالأدوية المخصصة لعلاج مرض السل قبل</p><p dir="RTL">أن تبدأ في استخدام سيمبوني.</p><p>&nbsp;</p><p>فيروس التهاب الكبد <em>(B HBV)</em> <strong>&nbsp;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp; أخبر طبيبك إذا كنت حاملاً للمرض أو إذا كنت تعاني من فيروس التهاب الكبد أو سبق وأن أصُبت به قبل أن تتناول سيمبوني.</p><p dir="RTL">&bull;&nbsp;&nbsp; أخبر طبيبك إذا كنت تعتقد أنك قد تكون عرضة للإصابة بفيروس التهاب الكبد .B</p><p dir="RTL">&bull;&nbsp;&nbsp; يتعين على طبيبك إجراء اختبار للكشف عن فيروس التهاب الكبد .B</p><p dir="RTL">&bull;&nbsp;&nbsp; قد يتسبب العلاج بمثبطات TNF مثل سيمبوني في تنشيط فيروس التهاب الكبد B في المرضى الذين يحملون هذا الفيروس</p><p dir="RTL">ويمكن أن يهدد الحياة في بعض الحالات.</p><p>&nbsp;</p><p dir="RTL">العدوى الفطرية الغزوية <em>&nbsp;</em></p><p dir="RTL">إذا كنت قد أقمت في منطقة أو سافرت إلى منطقة تكون فيها العدوى من نوع معين من الفطريات التي يمكن أن تؤثر على الرئتين أو أجزاء</p><p dir="RTL">أخرى بالجسم )تعُرف باسم داء النوسجات أو الفطار الكرواني أو الفطار البرعمي( شائعة الحدوث، فأخبر طبيبك على الفور. سل طبيبك إذا لم تكن تعلم إذا كانت هذه العدوى الفطرية شائعة الحدوث في المنطقة التي أقمت بها أو سافرت إليها.</p><p>&nbsp;</p><p><u>السرطان وأورام الغدد الليمفاوية</u>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كان قد سبق تشخيص حالتك على أنها أورام بالغدد الليمفاوية )نوع من سرطان الدم( أو أي نوع آخر من أنواع السرطانات قبل استخدام سيمبوني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم سيمبوني أو غيره من مثبطات TNF الأخرى، فقد تزيد مخاطر تطور أورام الغدد الليمفاوية أو أي سرطان آخر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون معدل خطورة تطور أورام الغدد الليمفاوية أكبر من المعدل المتوسط في المرضى المصابين بالتهاب المفصل الروماتويدي الحاد أو غيره من الالتهابات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهرت حالات سرطان، بما فيها أنواع غير مألوفة، في المرضى من الأطفال والبالغين الذين يتناولون عوامل تثبيط TNF والتي أدت في كثير من الأحيان إلى الوفاة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات نادرة، لوُحظ وجود أنواع خاصة وحادة من أورام الغدد الليمفاوية تسُمى ليمفومة الخلايا التائية المتعلقة بالكبد والطحال في المرضى الذين يتناولون مثبطات TNF الأخرى. كان معظم هؤلاء المرضى من المراهقين أو الشباب البالغين من الذكور. أدى هذا النوع من السرطان في الغالب إلى الوفاة. كما تلقى معظم هؤلاء المرضى الأدوية المعروفة مثل الآزاثيوبرين أو مركابتوبورين-6. أخبر طبيبك إذا كنت تتناول الآزاثيوبرين أو مركابتوبورين-6 مع سيمبوني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يزيد معدل خطورة الإصابة بالسرطان مع العلاج بدواء سيمبوني في الأشخاص الذين يعانون من داء الربو المستدام الحاد أو داء الانسداد الرئوي المزمن) COPD( أو المدخنين بشراهة. إذا كنت تعاني من داء الربو المستدام الحاد أو داء الانسداد الرئوي المزمن) COPD( أو كنت من المدخنين بشراهة، فعليك الرجوع إلى طبيبك لمعرفة العلاج بمثبطات TNF المناسب لك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تطورت حالة بعض المرضى الذين يتلقون العلاج بجوليموماب إلى أنواع معينة من سرطان الجلد. إذا طرأت أي تغييرات في مظهر الجلد أو عمليات نمو الجلد أثناء العلاج أو بعده، فأخبر طبيبك.</p><p><strong>&nbsp;</strong></p><p><u>السكتة القلبية</u>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا أصُبت بأعراض جديدة أو متفاقمة للسكتة القلبية. تشمل أعراض السكتة القلبية ضيق التنفس أو تورم القدمين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن سكتة قلبية جديدة وسكتة قلبية احتقانية متفاقمة مع مثبطات TNF.بما فيها سيمبوني , بعض هؤلاء المرضى توفوا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من سكتة قلبية خفيفة وتتلقى العلاج بدواء سيمبوني، يجب أن يتابعك الطبيب عن قرب.</p><p>&nbsp;</p><p><u>أمراض الجهاز العصبي</u>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا كان قد سبق تشخيص حالتك على أنها أعراض داء مزيل للميالين مثل داء التصلب المتعدد. قد تشمل الأعراض تغييرات في الرؤية أو ضعف في الذراعين أو الساقين أو تنميل أو نخز في أي جزء بالجسم. سيقرر طبيبك ما إذا كان عليك تلقي دواء سيمبوني أم لا.</p><p>&nbsp;</p><p><u>العمليات الجراحية أو عمليات الأسنان</u>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث مع طبيبك إذا كنت مقدمًا على إجراء أي عملية جراحية أو عملية أسنان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر جراحك أو طبيب الأسنان الذي يجري لك العملية بأنك تتلقى العلاج بدواء سيمبوني عن طريق إظهار بطاقة تنبيه المريض له.</p><p>&nbsp;</p><p dir="RTL"><u>داء المناعة الذاتية</u>&nbsp; أخبر طبيبك إذا ظهرت عليك أعراض المرض الذي يطُلق عليه داء الذئبة. تشمل الأعراض طفحًا جلدياً مستمرًا وحمى وألمًا بالمفاصل والإجهاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات نادرة، تطورت حالة المرضى الذين يتلقون العلاج بمثبطات TNF إلى داء الذئبة.</p><p>&nbsp;</p><p dir="RTL"><u>أمراض الدم</u> قد يفشل الجسم في بعض المرضى في ضخ ما يكفي من خلايا الدم التي تساعد جسمك على مقاومة العدوى أو التي تساعدك على إيقاف النزيف. إذا كنت تعاني من حمى دائمة أو كدمات أو نزيفاً بمنتهى السهولة أو تبدو شاحباً للغاية، فاتصل بطبيبك على الفور. قد يقرر طبيبك وقف العلاج.</p><p><strong>&nbsp;</strong></p><p dir="RTL">إذا لم تكن متأكدًا هل ينطبق عليك أي من الحالات المذكورة أعلاه أم لا، فتحدث مع طبيبك أو الصيدلي قبل استخدام سيمبوني.</p><p>&nbsp;</p><p><u>التطعيمات</u>&nbsp;</p><p dir="RTL">تحدث مع طبيبك إذا كنت قد حصلت على تطعيم أو من المقرر أن تحصل عليه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك عدم الحصول على بعض التطعيمات )الحية( أثناء استخدام سيمبوني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتسبب بعض التطعيمات في الإصابة بالعدوى. إذا تلقيتِ سيمبوني أثناء الحمل، فقد يتعرض طفلكِ لمخاطر هذه العدوى لمدة تصل إلى ما يقرب من ستة أشهر من آخر جرعة تلقيتها أثناء الحمل. من المهم أن تخبري أطباء طفلك وأخصائيي الرعاية الصحية الآخرين باستخدامك سيمبوني حتى يمكنهم تحديد متى ينبغي أن يحصل طفلكِ على أي تطعيم.</p><p>&nbsp;</p><p>العوامل المعدية العلاجية&nbsp;</p><p dir="RTL">تحدث إلى الطبيب إذا كنت قد تلقيت علاجًا أو من المقرر أن تتلقى علاجًا بالعوامل العلاجية لمكافحة العدوى مثل )تقطير BCG الذي يستخدم لعلاج</p><p dir="RTL">السرطان.(</p><p>&nbsp;</p><p dir="RTL"><u>التفاعلات </u>التحسسية</p><p dir="RTL">أخبر طبيبك على الفور إذا تطورت لديك أعراض تفاعل تحسسي بعد تلقيك العلاج بدواء سيمبوني. وقد تشمل أعراض التفاعل التحسسي تورم الوجه أو الشفاه أو الفم أو الحلق الذي قد يسبب صعوبة في الابتلاع أو التنفس أو طفحًا جلدياً أو الشرى أو تورم اليدين أو القدمين أو الكاحلين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تكون بعض هذه التفاعلات خطيرة أو نادرًا ما تهدد الحياة بالخطر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدثت بعض هذه التفاعلات بعد الحقن الأول بدواء سيمبوني.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُنُصح بحقن سيمبوني 100 مجم&nbsp; للأطفال أو المراهقين )أقل من 18 سنة.(</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وسيمبوني</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك أو الصيدلي إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى، بما في ذلك أي أدوية أخرى لعلاج التهاب المفصل الروماتويدي أو التهاب المفاصل الصدفي أو التهاب الفقار المقسط&nbsp; أو التهاب المفاصل الفقارية المحورية غير الشعاعية أو التهاب القولون التقرحي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ألا تتناول سيمبوني مع الأدوية التي تحتوي على المادة الفعالة لدواء أناكينرا أو أباتاسيبت. حيث تسُتخدم هذه الأدوية لعلاج الأمراض الروماتيزمية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك أو الصيدلي إذا كنت تتناول أي أدوية أخرى تؤثر على الجهاز المناعي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك عدم الحصول على بعض التطعيمات )الحية( أثناء استخدام سيمبوني.</p><p dir="RTL">&nbsp;إذا لم تكن متأكدًا هل ينطبق عليك أي من الحالات المذكورة أعلاه أم لا، فتحدث مع طبيبك أو الصيدلي قبل استخدام سيمبوني.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">تحدثي إلى طبيبكِ&nbsp; قبل استخدام سيمبوني إذا كنتِ:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاملاً أو تخططين لأن تصبحي حاملاً بينما تستخدمين سيمبوني. حيث إن آثار هذا الدواء على المرأة الحامل غير معروفة. لذلك لا ينُصح باستخدام سيمبوني عندما تكون المرأة حاملاً. وإذا كنتِ تتناولين علاج سيمبوني، يجب تجنب الحمل عن طريق استخدام وسائل منع حمل مناسبة أثناء فترة علاجكِ ولمدة 6 أشهر على الأقل بعد آخر حقن بدواء سيمبوني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل بدء الرضاعة، يجب أن يكون آخر علاج بدواء سيمبوني منذ 6 أشهر على الأقل. ويجب أن تتوقفي عن الرضاعة إذا كنتِ ستتناولين سيمبوني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتناولين سيمبوني أثناء حملك، فقد يكون طفلكِ عرضة للإصابة بالعدوى. لذلك من المهم أن تخبري طبيب الأطفال المعالج لطفلك وغيره من أطباء الرعاية الصحية عن استخدامكِ لـ سيمبوني قبل أن يتلقى الطفل أي لقاح )للحصول على مزيدٍ من المعلومات، انظر القسم الخاص بالتطعيم.(</p><p dir="RTL">إذا كنتِ حاملًا&nbsp; أو مُرضعًا، أو تعتقدين بأنكِ قد تكونين حاملاً أو تخططين لإنجاب طفل، فاستشيري طبيبكِ أو الصيدلي للحصول على النصيحة قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يكون لدواء سيمبوني تأثير بسيط على قدرتك على القيادة واستخدام الأدوات أو الآلات. ربما تحدث دوخة بعد تناولك سيمبوني. وإذا حدث ذلك، فتجنب القيادة أو استخدام الأدوات أو الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي سيمبوني على اللاتكس والسوربيتول</strong> <u>الحساسية ضد اللاتكس</u>&nbsp;</p><p dir="RTL">يحتوي جزء من القلم المعبأ مسبقاً، غطاء الإبرة، على مادة اللاتكس. لأن مادة اللاتكس قد تسبب تفاعلات تحسسية خطيرة، تحدث إلى طبيبك قبل استخدام سيمبوني، إذا كنت تعاني أنت أو موفر الرعاية لك من حساسية ضد اللاتكس.</p><p>&nbsp;</p><p><u>عدم تحمل السوربيتول</u></p><p dir="RTL">يحتوي سيمبوني على السوربيتول) E420(. إذا كان طبيبك قد أخبرك بأنك تعاني من عدم القدرة على تحمل بعض السكريات، فاستشره قبل تناول هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL">ينبغي استعمال هذا الدواء دائمًا وفقاً لتعليمات الطبيب أو الصيدلي. يجب عليك استشارة طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p>&nbsp;</p><p dir="RTL"><strong>ما الكمية التي يتم تناولها من سيمبوني </strong></p><p dir="RTL">يستخدم في علاج التهاب المفصل الروماتويدي والتهاب المفاصل الصدفي والتهاب المفاصل الفقارية المحورية، بما في ذلك التهاب الفقار المقسط والتهاب المفاصل الفقارية المحورية غير الشعاعية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصي بها هي 50 مجم تعُطى مرة واحدة في الشهر، في نفس التاريخ من كل شهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث إلى طبيبك قبل تناول جرعتك الرابعة. سيحدد طبيبك هل تستمر في العلاج باستخدام سيمبوني أم لا.</p><p dir="RTL">o إذا كان وزنك أكبر من 100 كجم، فقد يتم زيادة الجرعة إلى 100 مجم )محتوى قلم معبأ مسبقاً( تعُطى مرة واحدة في الشهر، في نفس التاريخ من كل شهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون التقرحي</p><p>&nbsp;</p><p dir="RTL">يوضح الجدول أدناه كيف ستستخدم هذا الدواء في الغالب.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">جرعة البداية 200 مجم )محتوى قلمين معبأين مسبقاً( تليها 100 مجم )محتوى قلم معبأ مسبقاً( بعد أسبوعين.</p></td><td style="vertical-align:top"><p dir="RTL">معالجة أولية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للمرضى الذين يقل وزنهم عن 80 كجم ،50 مجم )يجب استخدام محتوى قلم معبأ مسبقاً أو مِحْقنَةَ معبأة مسبقاً لهذه الجرعة 50 مجم( بعد 4 أسابيع من آخر علاج، ثم كل 4 أسابيع بعد ذلك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيما يتعلق بالمرضى الذين يبلغ وزنهم 80 كجم أو أكثر ،100 مجم )محتوى قلم واحد معبأ مسبقاً( بعد 4 أسابيع من آخر علاج، ثم كل 4 أسابيع بعد ذلك.</p></td><td style="vertical-align:top"><p dir="RTL">معالجة المداومة</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>كيف يتم تناول سيمبوني</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تناول سيمبوني عن طريق الحقن تحت الجلد )تحت الجلد.(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في البداية، ربما يحقنك طبيبك أو تحقنك الممرضة المتابعة لحالتك بدواء سيمبوني. ومع ذلك قد تقرر أنت أو طبيبك بأنك قد تحقن نفسك سيمبوني. وفي هذه الحالة، ستحصل على تدريب على كيفية حقن نفسك بدواء سيمبوني.</p><p dir="RTL">تحدث إلى طبيبك إذا كان لديك أي أسئلة تتعلق بحقن نفسك. ستجد &quot;إرشادات للحقن&quot; مفصّلة في نهاية هذه النشرة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا استخدمت سيمبوني أكثر مما ينبغي</strong></p><p dir="RTL">إذا استخدمت سيمبوني أو تم إعطاؤه لك أكثر من اللازم )إما عن طريق الحقن أكثر من اللازم في مرة واحدة أو استخدامه في كثير من الأوقات(، فتحدث إلى طبيبك أو الصيدلي على الفور. احتفظ دائمًا بعلبة الكرتون الخارجية وهذه النشرة معك، حتى وإن كانت فارغة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا كنت قد نسيت أن تستخدم سيمبوني</strong></p><p dir="RTL">إذا كنت قد نسيت أن تستخدم سيمبوني في التاريخ المحدد، فاحقن الجرعة المنسية بمجرد أن تتذكرها.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم جرعة مضاعفة لتعويض الجرعة المنسية.</p><p>&nbsp;</p><p dir="RTL">متى تحقن جرعتك التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت متأخرًا بأقل من أسبوعين، فاحقن الجرعة المنسية بمجرد أن تتذكرها واستمر على مواعيدك الأصلية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت متأخرًا بأكثر من أسبوعين، فاحقن الجرعة المنسية بمجرد أن تتذكرها وتحدث إلى طبيبك أو الصيدلي لتسأله عن توقيت أخذ الجرعة التالية.</p><p dir="RTL">إن لم تكن متأكدًا مما يجب القيام به، فتحدث إلى طبيبك أو الصيدلي.</p><p dir="RTL"><strong>إذا توقفت عن استخدام سيمبوني</strong></p><p dir="RTL">إذا كنت تفكر في إيقاف سيمبوني، فتحدث مع طبيبك أو الصيدلي بشأنه أولاً.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية عن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية على الرغم من عدم إصابة الجميع بها. قد يعاني بعض المرضى من آثار جانبية خطيرة وقد تتطلب حالتهم العلاج. تزداد مخاطر بعض الآثار الجانبية بنسبة أكبر مع تناول جرعة 100 مجم مقارنة بجرعة 50 مجم. قد تظهر الآثار الجانبية بعد فترة تصل إلى عدة أشهر من آخر حقن.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أياً من الآثار الجانبية التالية الخطيرة لدواء سيمبوني:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التفاعلات التحسسية التي قد تكون خطيرة، أو نادرًا ما تهدد الحياة )نادرة الحدوث(.</strong>&nbsp; وقد تشمل أعراض التفاعل التحسسي تورم الوجه أو الشفاه أو الفم أو الحلق الذي قد يسبب صعوبة في الابتلاع أو التنفس أو طفحًا جلدياً أو الشرى أو تورم اليدين أو القدمين أو الكاحلين. حدثت بعض هذه التفاعلات بعد الحقن الأول بدواء سيمبوني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العداوى الخطيرة )تشمل مرض السل والعدوى البكتيرية ومنها عداوى الدم الخطيرة والعدوى الفطرية الحادة والعداوى الانتهازية الأخرى( </strong></p><p dir="RTL"><strong>)شائعة الحدوث.(</strong>&nbsp; تشمل أعراض أي عدوى الحمى والإجهاد والسعال )المستدام( وضيق النفس وأعراض شبيهة بأعراض الأنفلونزا وفقدان الوزن والتعرق الليلي والإسهال والجروح ومشاكل الأسنان والشعور بالحرقان عند التبول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تنشيط فيروس التهاب الكبد </strong><strong>B</strong><strong> إذا كنت حاملاً للمرض أو سبق وأن أصُبت بفيروس التهاب الكبد </strong><strong>B</strong><strong> من قبل )نادرة الحدوث.(</strong>&nbsp; يمكن أن تشمل الأعراض اصفرار الجلد والعينين وتحول لون البول إلى اللون البني الداكن وألمًا في الجانب الأيمن من البطن والحمى والشعور بالغثيان والغثيان والشعور بالإجهاد الشديد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أمراض الجهاز العصبي مثل داء التصلب المتعدد )نادرة الحدوث.(</strong>&nbsp; يمكن أن تشمل أعراض أمراض الجهاز العصبي تغيرات في الرؤية وضعف في الذراعين أو الساقين وتنميلًا أو وخزًا في أي جزء من جسمك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان العقد اللمفاوية )أورام الغدد اللمفاوية( )نادر الحدوث.(</strong>&nbsp; يمكن أن تشمل أعراض أورام الغدد الليمفاوية تورم العقد الليمفاوية أو فقدان الوزن أو الحمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>السكتة القلبية )نادرة الحدوث.(</strong>&nbsp; يمكن أن تشمل أعراض السكتة القلبية ضيق النفس أو تورم القدمين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>علامات اضطراب جهاز المناعة التي تسمى ب : </strong>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>داء الذئبة )نادرة الحدوث.(</strong>&nbsp; يمكن أن تشمل الأعراض آلامًا في المفاصل أو طفحًا جلدياًّ على الخدين أو الذراعين الذي يكون حسّاسًا لأشعة الشمس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الساركويد )نادر(</strong>. ويمكن أن تشمل الأعراض السعال المستمر، ويجري ضيق في التنفس، ألم في الصدر، الحمى، تورم الغدد الليمفاوية، وفقدان الوزن، والطفح الجلدي، وعدم وضوح الرؤية.</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تورم الأوعية الدموية الصغيرة )الأوعية الدموية( )نادرة(.</strong> ويمكن أن تشمل الأعراض الحمى والصداع وفقدان الوزن، تعرق ليلي، والطفح الجلدي، ومشاكل عصبية مثل الخدر ووخز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان الجلد )غير مألوف(</strong>. أعراض سرطان الجلد ويمكن أن تشمل التغييرات في مظهر بشرتك أو أورام على الجلد</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أمراض الدم )شائعة الحدوث.(</strong>&nbsp; يمكن أن تشمل أعراض أمراض الدم حمى دائمة أو كدمات أو نزيف بمنتهى السهولة أو قد تبدو شاحباً للغاية.</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أياً من الأعراض أعلاه.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم )اللوكيميا( )نادر(.</strong> أعراض سرطان الدم ويمكن أن تشمل حمى، والشعور بالتعب، والالتهابات المتكررة، والكدمات، وتعرق ليلي</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>لوُحظت الآثار الجانبية الإضافية التالية مع سيمبوني: </strong></p><p dir="RTL"><u>الآثار الجانبية الشائعة جدًا )قد تؤثر على أكثر من </u><u>1</u><u> في كل </u><u>10</u><u> أشخاص:(</u>&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات المجرى التنفسي العلوي أو التهاب الحلق أو البحة أو رشح في الأنف</p><p>&nbsp;</p><p><u>الآثار الجانبية الشائعة )قد تؤثر على </u><u>1 في كل </u><u>10 أشخاص:(</u>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحوصات الكبد غير الطبيعية )زيادة إنزيمات الكبد( التي يتم التوصل إليها أثناء اختبارات الدم التي يجريها طبيبك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوخة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتنميل أو الشعور بالوخز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية السطحية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخُرَاجات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى البكتيرية )مثل التهاب الهلَلَ(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم الحمراء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيجابية اختبار داء الذئبة في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات التحسسية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالرغبة في القيء )الغثيان(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأنفلونزا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشعب الهوائية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب الأنفية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القرح الباردة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو وضيق النفس والأزيز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في المعدة والأمعاء التي تشمل التهاب بطانة المعدة والقولون الذي قد يسبب الحمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وقرَُح في الفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع الحقن )تشمل احمرارًا وتيبسًا وألمًا وكدمات وحكة ووخزًا وتهيُّجًا(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحكة في الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسور في العظام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الصدر</p><p>&nbsp;</p><p dir="RTL"><u>الآثار الجانبية غير الشائعة )قد تؤثر على </u><u>1</u><u> في كل </u><u>100</u><u> شخصٍ(:</u>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض السرطان، ومنها سرطان الجلد والأورام غير السرطانية أو الكتل، بما في ذلك شامات الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصدفية )بما في ذلك راحة اليدين و/أو أخمص القدم و/أو شكل بثور الجلد(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم البيضاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزيج من انخفاض في الصفائح الدموية وأعداد كرات الدم الحمراء والبيضاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات السكر في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات نسبة الكوليسترول في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات التوازن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الرؤية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بنبض غير منتظم في القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضييق الأوعية الدموية في القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلطات الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة التهاب مزمنة في الرئة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاع حمضي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصاة المرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الثدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الحيض</p><p>&nbsp;</p><p dir="RTL"><u>الآثار الجانبية النادرة )قد تؤثر على </u><u>1</u><u> في كل </u><u>1</u><u>,</u><u>000</u><u> شخصٍ(:</u>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل نخاع العظام في إنتاج كرات الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل أو الأنسجة المحيطة بها</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف التئام الجروح</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية في الأعضاء الداخلية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم ميلانيني )نوع من سرطان الجلد(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقشر، تقشر الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات المناعة التي قد تؤثر على الرئتين والجلد والعقد الليمفاوية )الأكثر شيوعًا من بينها الساركويد(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو تغير في اللون في أصابع اليدين أو القدمين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المثانة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية في جلدك التي تؤدي إلى طفح جلدي</p><p>&nbsp;</p><p dir="RTL"><u>الآثار الجانبية غير المعروف معدل تكرارها:</u>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلية ميركل )نوع من سرطان الجلد(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم النادر الذي يؤثر في أغلب الحالات على الشباب )سرطان الغدد الليمفاوية التائية( <strong>الإبلا&nbsp; عن الآثار الجانبية </strong></p><p dir="RTL">إذا واجهت أي آثار جانبية، فتحدث مع طبيبك أو الصيدلي أو الممرضة المتابعة لحالتك بشأنها.&nbsp; ويتضمن ذلك أي آثار جانبية محتملة غير مُدرجة في هذه النشرة.&nbsp;</p><p dir="RTL"><strong>الإبلا&nbsp; عن الآثار الجانبية </strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; <strong>المملكة العربية السعودية </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:637px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني لليقظة الصيدلانية والسلامة الدوائية) NPC( o فاكس: 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بالمركز الوطني لليقظة الصيدلانية والسلامة الدوائية) NPC( على رقم: 2038222-11-966+، تحويلات: 2340-2334-2354-2353-2356-2317. o رقم الهاتف المجاني: 8002490000 o بريد إلكتروني: <u>npc.drug@sfda.gov.sa</u></p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;www.sfda.gov.sa/npc :الموقع الإلكتروني</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; <strong>باقي دول مجلس التعاون الخليجي: </strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:637px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;يرجى الاتصال بالسلطة المختصة ذات الصلة.</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:637px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>ان هذا الدواء </strong></p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك وإستهلاكه خلافا للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إتبع بدقة وصفة الطبيب وطريقة الإستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك فالطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون وصفة طبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تترك الدواء في متناول أيدي الأطفال</p><p>&nbsp;</p><p dir="RTL"><strong>مجلس وزراء الصحة العرب</strong><strong> </strong><strong>و اتحاد الصيادلة العرب </strong></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحُفظ الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز استعمال هذا الدواء بعد انتهاء تاريخ الصلاحية الذي يظهر على الشريط اللاصق وعلى الكرتونة بعد الحروف&quot; EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يخُزن في الثلاجة )من 2 إلى 8 درجات مئوية(. لا تجمد العبوة .لا ترج العبوة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بالقلم المعبأ مسبقاً في علبة الكرتون الخارجية لحمايته من الضوء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء إذا لاحظت أن لون السائل غير شفاف إلى مائل إلى اللون الأصفر الفاتح أو إذا كان غائمًا أو يحتوي على جسيمات غريبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احذر التخلص من أي أدوية عبر مياه الصرف أو في النفايات المنزلية. اسأل طبيبك أو الصيدلي عن كيفية التخلص من الأدوية التي لم تعد</p><p dir="RTL">بحاجة لاستخدامها. سوف تساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحتوي عليه سيمبوني </strong></p><p dir="RTL">المادة الفعالة هي جوليموماب. قلم واحد 1 مل معبأ مسبقاً يحتوي على 100 مجم من جوليموماب.</p><p dir="RTL">المكونات الأخرى هي السوربيتول) E420( و الهيستيدين-إل ومونوهيدرات مونوهيدروكلوريد الهيستيدين-إل وبوليسوربات 80 وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو سيمبوني وما محتويات العبوة</strong></p><p dir="RTL">يتم توفير دواء سيمبوني كمحلول للحقن في قلم معبأ مسبقاً للاستخدام لمرة واحدة. يتوفر سيمبوني في عبوات تحتوي على قلم واحد معبأ مسبقاً وعبوات متعددة تحتوي على 3 )3 عبوات في 1( أقلام معبأة مسبقاً. قد لا تتوفر العبوات من جميع الأحجام بالسوق.</p><p>المحلول قريب من اللون البراق قليلاً )يتميز ببريق مثل اللؤلؤ(، كما أنه عديم اللون إلى الأصفر الفاتح وقد يحتوي على عدد قليل من الجزيئات البيضاء أو الشفافة من البروتين. لا تستخدم سيمبوني إذا تغير لون المحلول أو أصبح غائمًا أو يمكنك رؤية جسيمات غريبة فيه.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعّة</strong></p><p dir="RTL">انظر العبوة الخارجية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في  6 ديسمبر 2016 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Simponi 100 mg solution for injection in pre filled pen.
Simponi 100 mg solution for injection in pre filled syringe.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Simponi 100 mg solution for injection in pre filled pen
Each 1 mL pre filled pen contains 100 mg of golimumab*.

Simponi 100 mg solution for injection in pre filled syringe
Each 1 mL pre filled syringe contains 100 mg of golimumab*.

* Human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology.

Excipient with known effect:

Each pre filled pen contains 41 mg sorbitol per 100 mg dose.

Each pre filled syringe contains 41 mg sorbitol per 100 mg dose.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in pre filled pen (injection), SmartJect

Solution for injection in pre filled syringe (injection)

The solution is clear to slightly opalescent, colourless to light yellow.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Rheumatoid arthritis (RA)</u></p><p>Simponi, in combination with methotrexate (MTX), is indicated for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease‑modifying anti‑rheumatic drug (DMARD) therapy including MTX has been inadequate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.</p><p>&nbsp;</p><p>Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X‑ray and to improve physical function.</p><p>&nbsp;</p><p>For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50&nbsp;mg SmPC.</p><p>&nbsp;</p><p><u>Psoriatic arthritis (PsA)</u></p><p>Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X‑ray in patients with polyarticular symmetrical subtypes of the disease (see&nbsp;section&nbsp;5.1) and to improve physical function.</p><p>&nbsp;</p><p><u>Axial spondyloarthritis</u></p><p><em>Ankylosing spondylitis (AS)</em></p><p>Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.</p><p>&nbsp;</p><p><em>Non‑radiographic axial spondyloarthritis (nr‑Axial SpA)</em></p><p>Simponi is indicated for the treatment of adults with severe, active non‑radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C‑reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p><u>Ulcerative colitis (UC)</u></p><p>Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6‑mercaptopurine (6‑MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Simponi treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non‑radiographic axial spondyloarthritis, or ulcerative colitis. Patients treated with Simponi should be given the Patient Alert Card.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Rheumatoid arthritis</em></p><p>Simponi 50&nbsp;mg given once a month, on the same date each month.</p><p>Simponi should be given concomitantly with MTX.</p><p><u>&nbsp;</u></p><p><em>Psoriatic arthritis, ankylosing spondylitis, or non‑radiographic axial spondyloarthritis</em></p><p>Simponi 50&nbsp;mg given once a month, on the same date each month.</p><p>&nbsp;</p><p>For all of the above indications, available data suggest that clinical response is usually achieved within 12 to 14&nbsp;weeks of treatment (after 3‑4&nbsp;doses). Continued therapy should be reconsidered in patients who show no evidence of therapeutic benefit within this time period.</p><p>&nbsp;</p><p>Patients with bodyweight greater than 100&nbsp;kg</p><p>For all of the above indications, in patients with RA, PsA, AS, or nr‑Axial SpA with a body weight of more than 100&nbsp;kg who do not achieve an adequate clinical response after 3 or 4&nbsp;doses, increasing the dose of golimumab to 100&nbsp;mg once a month may be considered, taking into account the increased risk of certain serious adverse drug reactions with the 100&nbsp;mg dose compared with the 50&nbsp;mg dose (see&nbsp;section&nbsp;4.8). Continued therapy should be reconsidered in patients who show no evidence of therapeutic benefit after receiving 3 to 4&nbsp;additional doses of 100&nbsp;mg.</p><p><u>&nbsp;</u></p><p><em>Ulcerative colitis</em></p><p>Patients with body weight less than 80&nbsp;kg</p><p>Simponi given as an initial dose of 200&nbsp;mg, followed by 100&nbsp;mg at week&nbsp;2, then 50&nbsp;mg every 4&nbsp;weeks, thereafter (see section&nbsp;5.1).</p><p><em>&nbsp;</em></p><p>Patients with body weight greater than or equal to 80&nbsp;kg</p><p>Simponi given as an initial dose of 200&nbsp;mg, followed by 100&nbsp;mg at week&nbsp;2, then 100&nbsp;mg every 4&nbsp;weeks, thereafter (see section&nbsp;5.1).</p><p><u>&nbsp;</u></p><p>During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice guidelines.</p><p>&nbsp;</p><p>Available data suggest that clinical response is usually achieved within 12‑14&nbsp;weeks of treatment (after 4&nbsp;doses). Continued therapy should be reconsidered in patients who show no evidence of therapeutic benefit within this time period.</p><p>&nbsp;</p><p><u>Missed dose</u></p><p>If a patient forgets to inject Simponi on the planned date, the forgotten dose should be injected as soon as the patient remembers. Patients should be instructed not to inject a double dose to make up for the forgotten dose.</p><p>&nbsp;</p><p>The next dose should be administered based on the following guidance:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the dose is less than 2&nbsp;weeks late, the patient should inject his/her forgotten dose and stay on his/her original schedule.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the dose is more than 2&nbsp;weeks late, the patient should inject his/her forgotten dose and a new schedule should be established from the date of this injection.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><em>Elderly (&ge;&nbsp;65&nbsp;years)</em></p><p>No dose adjustment is required in the elderly.</p><p><em>&nbsp;</em></p><p><em>Renal and hepatic impairment</em></p><p>Simponi has not been studied in these patient populations. No dose recommendations can be made.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Simponi 100&nbsp;mg is not recommended in children aged less than 18.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>Simponi is for subcutaneous use. After proper training in subcutaneous injection technique, patients may self‑inject with Simponi if their physician determines that this is appropriate, with medical follow‑up as necessary. Patients should be instructed to inject the full amount of Simponi according to the comprehensive instructions for administration provided in the package leaflet. If multiple injections are required, the injections should be administered at different sites on the body.</p><p>&nbsp;</p><p>For administration instructions, see&nbsp;section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active tuberculosis (TB) or other severe infections such as sepsis, and opportunistic infections (see section 4.4).

Moderate or severe heart failure (NYHA class III/IV) (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Infections</u></p><p>Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Simponi. Because the elimination of golimumab may take up to 5&nbsp;months, monitoring should be continued throughout this period. Further treatment with Simponi must not be given if a patient develops a serious infection or sepsis (see&nbsp;section&nbsp;4.3).</p><p>&nbsp;</p><p>Simponi should not be given to patients with a clinically important, active infection. Caution should be exercised when considering the use of Simponi in patients with a chronic infection or a history of recurrent infection. Patients should be advised of, and avoid exposure to, potential risk factors for infection as appropriate.</p><p>&nbsp;</p><p>Patients taking TNF‑blockers are more susceptible to serious infections.</p><p>Bacterial (including sepsis and pneumonia), mycobacterial (including TB), invasive fungal and opportunistic infections, including fatalities, have been reported in patients receiving Simponi. Some of these serious infections have occurred in patients on concomitant immunosuppressive therapy that, in addition to their underlying disease, could predispose them to infections. Patients who develop a new infection while undergoing treatment with Simponi should be monitored closely and undergo a complete diagnostic evaluation. Administration of Simponi should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled.</p><p>&nbsp;</p><p>For patients who have resided in or travelled to regions where invasive fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of Simponi treatment should be carefully considered before initiation of Simponi therapy. In at-risk patients treated with Simponi, an invasive fungal infection should be suspected if they develop a serious systemic illness. Diagnosis and administration of empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the care of patients with invasive fungal infections, if feasible.</p><p>&nbsp;</p><p><em>Tuberculosis</em></p><p>There have been reports of tuberculosis in patients receiving Simponi. It should be noted that in the majority of these reports, tuberculosis was extrapulmonary presenting as either local or disseminated disease.</p><p>&nbsp;</p><p>Before starting treatment with Simponi, all patients must be evaluated for both active and inactive (&lsquo;latent&rsquo;) tuberculosis. This evaluation should include a detailed medical history with personal history of tuberculosis or possible previous contact with tuberculosis and previous and/or current immunosuppressive therapy. Appropriate screening tests, i.e. tuberculin skin or blood test and chest X‑ray, should be performed in all patients (local recommendations may apply). It is recommended that the conduct of these tests should be recorded in the patient&rsquo;s alert card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.</p><p>&nbsp;</p><p>If active tuberculosis is diagnosed, Simponi therapy must not be initiated (see&nbsp;section&nbsp;4.3).</p><p>&nbsp;</p><p>If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted. In all situations described below, the benefit/risk balance of Simponi therapy should be very carefully considered.</p><p>&nbsp;</p><p>If inactive (&lsquo;latent&rsquo;) tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti‑tuberculosis therapy before the initiation of Simponi, and in accordance with local recommendations.</p><p>&nbsp;</p><p>In patients who have several or significant risk factors for tuberculosis and have a negative test for latent tuberculosis, anti‑tuberculosis therapy should be considered before the initiation of Simponi. Use of anti‑tuberculosis therapy should also be considered before the initiation of Simponi in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.</p><p>&nbsp;</p><p>Cases of active tuberculosis have occurred in patients treated with Simponi during and after treatment for latent tuberculosis. Patients receiving Simponi should be monitored closely for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis, patients who are on treatment for latent tuberculosis, or patients who were previously treated for tuberculosis infection.</p><p>&nbsp;</p><p>All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g. persistent cough, wasting/weight loss, low‑grade fever) appear during or after Simponi treatment.</p><p><em>&nbsp;</em></p><p><u>Hepatitis B virus reactivation</u></p><p>Reactivation of hepatitis B has occurred in patients receiving a TNF‑antagonist including Simponi, who are chronic carriers of this virus (i.e. surface antigen positive). Some cases have had fatal outcome.</p><p>&nbsp;</p><p>Patients should be tested for HBV infection before initiating treatment with Simponi. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.</p><p>&nbsp;</p><p>Carriers of HBV who require treatment with Simponi should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. Adequate data of treating patients who are carriers of HBV with anti‑viral therapy in conjunction with TNF‑antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV reactivation, Simponi should be stopped and effective anti‑viral therapy with appropriate supportive treatment should be initiated.</p><p>&nbsp;</p><p><u>Malignancies and lymphoproliferative disorders</u></p><p>The potential role of TNF‑blocking therapy in the development of malignancies is not known. Based on the current knowledge, a possible risk for the development of lymphomas, leukaemia or other malignancies in patients treated with a TNF‑antagonist cannot be excluded. Caution should be exercised when considering TNF‑blocking therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy.</p><p>&nbsp;</p><p><em>Paediatric malignancy</em></p><p>Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22&nbsp;years of age) treated with TNF‑blocking agents (initiation of therapy &le;&nbsp;18&nbsp;years of age) in the post marketing setting. Approximately half the cases were lymphomas. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression. A risk for the development of malignancies in children and adolescents treated with TNF‑blockers cannot be excluded.</p><p>&nbsp;</p><p><em>Lymphoma and leukaemia</em></p><p>In the controlled portions of clinical trials of all the TNF‑blocking agents including Simponi, more cases of lymphoma have been observed among patients receiving anti‑TNF treatment compared with control patients. During the Simponi Phase IIb and Phase III clinical trials in RA, PsA and AS, the incidence of lymphoma in Simponi‑treated patients was higher than expected in the general population. Cases of leukaemia have been reported in patients treated with Simponi. There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long‑standing, highly active, inflammatory disease, which complicates risk estimation.</p><p>&nbsp;</p><p>Rare post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with other TNF-blocking agents (see section&nbsp;4.8). This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. The majority of cases have occurred in adolescent and young adult males with nearly all on comcomitant treatment with azathioprine (AZA) or 6‑mercaptopurine (6&ndash;MP) for inflammatory bowel disease. The potential risk with the combination of AZA or 6‑MP and Simponi should be carefully considered. A risk for the development for hepatosplenic T‑cell lymphoma in patients treated with TNF-blockers cannot be excluded.</p><p><em>&nbsp;</em></p><p><em>Malignancies other than lymphoma</em></p><p>In the controlled portions of the Simponi Phase IIb and Phase III clinical trials in RA, PsA, AS, and UC, the incidence of non‑lymphoma malignancies (excluding non‑melanoma skin cancer) was similar between the Simponi and the control groups.</p><p>&nbsp;</p><p><em>Colon dysplasia/carcinoma</em></p><p>It is not known if golimumab treatment influences the risk for developing dysplasia or colon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per local recommendations. In patients with newly diagnosed dysplasia treated with Simponi, the risks and benefits to the individual patient must be carefully reviewed and consideration should be given to whether therapy should be continued.</p><p>&nbsp;</p><p>In an exploratory clinical trial evaluating the use of Simponi in patients with severe persistent asthma, more malignancies were reported in patients treated with Simponi compared with control patients (see section&nbsp;4.8). The significance of this finding is unknown.</p><p>&nbsp;</p><p>In an exploratory clinical trial evaluating the use of another anti‑TNF agent, infliximab, in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung or head and neck, were reported in infliximab‑treated patients compared with control patients. All patients had a history of heavy smoking. Therefore, caution should be exercised when using any TNF‑antagonist in COPD patients, as well as in patients with an increased risk of malignancy due to heavy smoking.</p><p>&nbsp;</p><p><em>Skin cancers</em></p><p>Melanoma has been reported in patients treated with TNF‑blocking agents, including Simponi. Merkel cell carcinoma has been reported in patients treated with other TNF‑blocking agents (see&nbsp;section&nbsp;4.8). Periodic skin examination is recommended, particularly for patients with risk factors for skin cancer.</p><p>&nbsp;</p><p><u>Congestive heart failure (CHF)</u></p><p>Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers, including Simponi. Some cases had a fatal outcome. In a clinical trial with another TNF‑antagonist worsening congestive heart failure and increased mortality due to CHF have been observed. Simponi has not been studied in patients with CHF. Simponi should be used with caution in patients with mild heart failure (NYHA class I/II). Patients should be closely monitored and Simponi must be discontinued in patients who develop new or worsening symptoms of heart failure (see&nbsp;section&nbsp;4.3).</p><p>&nbsp;</p><p><u>Neurological events</u></p><p>Use of TNF‑blocking agents, including Simponi, has been associated with cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and peripheral demyelinating disorders. In patients with pre‑existing or recent onset of demyelinating disorders, the benefits and risks of anti‑TNF treatment should be carefully considered before initiation of Simponi therapy. Discontinuation of Simponi should be considered if these disorders develop (see&nbsp;section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Surgery</u></p><p>There is limited safety experience of Simponi treatment in patients who have undergone surgical procedures, including arthroplasty. The long half‑life should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on Simponi should be closely monitored for infections, and appropriate actions should be taken.</p><p>&nbsp;</p><p><u>Immunosuppression</u></p><p>The possibility exists for TNF‑blocking agents, including Simponi, to affect host defences against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses.</p><p>&nbsp;</p><p><u>Autoimmune processes</u></p><p>The relative deficiency of TNF<sub>a</sub> caused by anti‑TNF therapy may result in the initiation of an autoimmune process. If a patient develops symptoms suggestive of a lupus‑like syndrome following treatment with Simponi and is positive for antibodies against double‑stranded DNA, treatment with Simponi should be discontinued (see section&nbsp;4.8).</p><p><u>&nbsp;</u></p><p><u>Haematologic reactions</u></p><p>There have been post‑marketing reports of pancytopaenia, leucopaenia, neutropaenia, aplastic anaemia, and thrombocytopaenia in patients receiving TNF‑blockers. Cytopaenias including pancytopaenia have been infrequently reported with Simponi in clinical trials. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor). Discontinuation of Simponi therapy should be considered in patients with confirmed significant haematologic abnormalities.</p><p>&nbsp;</p><p><u>Concurrent administration of TNF‑antagonists and anakinra</u></p><p>Serious infections and neutropenia were seen in clinical studies with concurrent use of anakinra and another TNF‑blocking agent, etanercept, with no added clinical benefit. Because of the nature of the adverse events seen with this combination therapy, similar toxicities may also result from the combination of anakinra and other TNF‑blocking agents. The combination of Simponi and anakinra is not recommended.</p><p>&nbsp;</p><p><u>Concurrent administration of TNF‑antagonists and abatacept</u></p><p>In clinical studies concurrent administration of TNF‑antagonists and abatacept has been associated with an increased risk of infections including serious infections compared to TNF‑antagonists alone, without increased clinical benefit. The combination of Simponi and abatacept is not recommended.</p><p>&nbsp;</p><p><u>Concurrent administration with other biological therapeutics</u></p><p>There is insufficient information regarding the concomitant use of Simponi with other biological therapeutics used to treat the same conditions as Simponi. The concomitant use of Simponi with these biologics is not recommended because of the possibility of an increased risk of infection, and other potential pharmacological interactions.</p><p>&nbsp;</p><p><u>Switching between biological DMARDs</u></p><p>Care should be taken and patients should continue to be monitored when switching from one biologic to another, since overlapping biological activity may further increase the risk for adverse events, including infection.</p><p>&nbsp;</p><p><u>Vaccinations/therapeutic infectious agents</u></p><p>Patients treated with Simponi may receive concurrent vaccinations, except for live vaccines (see sections&nbsp;4.5 and 4.6). In patients receiving anti-TNF therapy, limited data are available on the response to vaccination with live vaccines or on the secondary transmission of infection by live vaccines. Use of live vaccines could result in clinical infections, including disseminated infections.</p><p><u>&nbsp;</u></p><p>Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g. BCG bladder instillation for the treatment of cancer) could result in clinical infections, including disseminated infections. It is recommended that therapeutic infectious agents not be given concurrently with Simponi.</p><p><u>&nbsp;</u></p><p><u>Allergic reactions</u></p><p>In post‑marketing experience, serious systemic hypersensitivity reactions (including anaphylactic reaction) have been reported following Simponi administration. Some of these reactions occurred after the first administration of Simponi. If an anaphylactic reaction or other serious allergic reactions occur, administration of Simponi should be discontinued immediately and appropriate therapy initiated.</p><p>&nbsp;</p><p><em>Latex sensitivity</em></p><p>The needle cover on the pre‑filled pen or the pre‑filled syringe is manufactured from dry natural rubber containing latex, and may cause allergic reactions in individuals sensitive to latex.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly (&ge;&nbsp;65&nbsp;years)</em></p><p>In the Phase III studies in RA, PsA, AS, and UC, no overall differences in adverse events (AEs), serious adverse events (SAEs), and serious infections in patients age&nbsp;65 or older who received Simponi were observed compared with younger patients. However, caution should be exercised when treating the elderly and particular attention paid with respect to occurrence of infections. There were no patients age&nbsp;45&nbsp;and over in the nr‑Axial SpA study.</p><p>&nbsp;</p><p><em>Renal and hepatic impairment</em></p><p>Specific studies of Simponi have not been conducted in patients with renal or hepatic impairment. Simponi should be used with caution in subjects with impaired hepatic function (see&nbsp;section&nbsp;4.2).</p><p><em>&nbsp;</em></p><p><u>Excipients</u></p><p>Simponi contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take Simponi.</p><p><u>&nbsp;</u></p><p><u>Potential for medication errors</u></p><p>Simponi is registered in 50&nbsp;mg and 100&nbsp;mg strengths for subcutaneous administration. It is important that the right strength is used to administer the correct dose as indicated in the posology (see section&nbsp;4.2). Care should be taken to provide the right strength to ensure that patients are not underdosed or overdosed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p><p><u>Concurrent use with other biological therapeutics</u></p><p>The combination of Simponi with other biological therapeutics used to treat the same conditions as Simponi, including anakinra and abatacept is not recommended (see&nbsp;section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Live vaccines/therapeutic infectious agents</u></p><p>Live vaccines should not be given concurrently with Simponi (see&nbsp;sections&nbsp;4.4 and 4.6).</p><p>&nbsp;</p><p>Therapeutic infectious agents should not be given concurrently with Simponi (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Methotrexate</u></p><p>Although concomitant use of MTX results in higher steady‑state trough concentrations of Simponi in patients with RA, PsA or AS, the data do not suggest the need for dose adjustment of either Simponi or MTX (see&nbsp;section&nbsp;5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6&nbsp;months after the last golimumab treatment.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>There are no adequate data on the use of golimumab in pregnant women. Due to its inhibition of TNF, golimumab administered during pregnancy could affect normal immune responses in the newborn. Studies in animals do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see&nbsp;section&nbsp;5.3). The use of golimumab in pregnant women is not recommended; golimumab should be given to a pregnant woman only if clearly needed.</p><p>&nbsp;</p><p>Golimumab crosses the placenta. Following treatment with a TNF‑blocking monoclonal antibody during pregnancy, the antibody has been detected for up to 6&nbsp;months in the serum of the infant born by the treated woman.<em> </em>Consequently, these infants may be at increased risk of infection. Administration of live vaccines to infants exposed to golimumab <em>in utero</em> is not recommended for 6&nbsp;months following the mother&rsquo;s last golimumab injection during pregnancy (see&nbsp;sections&nbsp;4.4 and 4.5).</p><p><u>&nbsp;</u></p><p><u>Breast‑feeding</u></p><p>It is not known whether golimumab is excreted in human milk or absorbed systemically after ingestion. Golimumab was shown to pass over to breast milk in monkeys, and because human immunoglobulins are excreted in milk, women must not breast feed during and for at least 6&nbsp;months after golimumab treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No animal fertility studies have been conducted with golimumab. A fertility study in mice, using an analogous antibody that selectively inhibits the functional activity of mouse TNF&alpha;, showed no relevant effects on fertility (see&nbsp;section&nbsp;5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Simponi may have a minor influence on the ability to drive and use machines. Dizziness may occur following administration of Simponi (see&nbsp;section&nbsp;4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In the controlled period of the pivotal trials in RA, PsA, AS, nr‑Axial SpA, and UC, upper respiratory tract infection was the most common adverse drug reaction (ADR) reported in 12.6% of golimumab‑treated patients compared with 11.0% of control patients. The most serious ADRs that have been reported for golimumab include serious infections (including sepsis, pneumonia, TB, invasive fungal and opportunistic infections), demyelinating disorders, HBV reactivation, CHF, autoimmune processes (lupus‑like syndrome), haematologic reactions, serious systemic hypersensitivity (including anaphylactic reaction), vasculitis, lymphoma and leukaemia (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>ADRs observed in clinical studies and reported from world‑wide post‑marketing use of golimumab are listed in Table&nbsp;1. Within the designated system organ classes, the adverse drug reactions are listed under headings of frequency and using the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table&nbsp;1</strong></p><p><strong>Tabulated list of ADRs</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Upper respiratory tract infection (nasopharyngitis, pharyngitis, laryngitis and rhinitis)</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Bacterial infections (such as cellulitis), lower respiratory tract infection (such as pneumonia), viral infections (such as influenza and herpes), bronchitis, sinusitis, superficial fungal infections, abscess</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Sepsis including septic shock, pyelonephritis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Tuberculosis, opportunistic infections (such as invasive fungal infections [histoplasmosis, coccidioidomycosis, pneumocytosis], bacterial, atypical mycobacterial infection and protozoal), hepatitis B reactivation, bacterial arthritis, infective bursitis</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms, benign, malignant and unspecified</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Neoplasms (such as skin cancer, squamous cell carcinoma and melanocytic naevus)</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Lymphoma, leukaemia, melanoma</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Merkel cell carcinoma*, hepatosplenic T-cell lymphoma*</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Common:</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Leucopaenia, thrombocytopaenia, pancytopaenia</p></td></tr><tr><td><p>Rare:</p></td><td style="vertical-align:top"><p>Aplastic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Allergic reactions (bronchospasm, hypersensitivity, urticaria), autoantibody positive</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Serious systemic hypersensitivity reactions (including anaphylactic reaction), vasculitis (systemic), sarcoidosis</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Thyroid disorder (such as hypothyroidism, hyperthyroidism and goitre)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Blood glucose increased, lipids increased</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Depression, insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dizziness, headache, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Balance disorders</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Demyelinating disorders (central and peripheral), dysguesia</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Visual disorders (such as blurred vision and decreased visual acuity), conjunctivitis, eye allergy (such as pruritis and irritation)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Arrhythmia, ischemic coronary artery disorders</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Congestive heart failure (new onset or worsening)</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Thrombosis (such as deep venous and aortic), flushing</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Raynaud&rsquo;s phenomenon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Asthma and related symptoms (such as wheezing and bronchial hyperactivity)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Interstitial lung disease</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspepsia, gastrointestinal and abdominal pain, nausea, gastrointestinal inflammatory disorders (such as gastritis and colitis), stomatitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Constipation, gastro‑oesophageal reflux disease</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased, aspartate aminotransferase increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Cholelithiasis, hepatic disorders</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pruritus, rash, alopecia, dermatitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Bullous skin reactions, psoriasis (new onset<em> </em>or worsening of pre‑existing psoriasis, palmar/plantar and pustular), urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Skin exfoliation, vasculitis (cutaneous)</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Lupus‑like syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Bladder disorders, renal disorders</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Breast disorders, menstrual disorders</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pyrexia, asthenia, injection site reaction (such as injection site erythema, urticaria, induration, pain, bruising, pruritus, irritation and paraesthesia), chest discomfort</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Impaired healing</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Bone fractures</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*:&nbsp;&nbsp; Observed with other TNF‑blocking agents, but not observed in clinical studies with golimumab.</p></td></tr></tbody></table><p>&nbsp;</p><p>Throughout this section, median duration of follow-up (approximately 4&nbsp;years) is generally presented for all golimumab use. Where golimumab use is described by dose, the median duration of follow‑up varies (approximately 2&nbsp;years for 50&nbsp;mg dose, approximately 3&nbsp;years for 100&nbsp;mg dose) as patients may have switched between doses.</p><p><u>&nbsp;</u></p><p><u>Description of selected adverse drug reactions</u></p><p>&nbsp;</p><p><em>Infections</em></p><p>In the controlled period of pivotal trials, upper respiratory tract infection was the most common adverse reaction reported in 12.6% of golimumab‑treated patients (incidence per 100&nbsp;subject‑years: 60.8; 95% CI: 55.0, 67.1) compared with 11.0% of control patients (incidence per 100&nbsp;subject‑years: 54.5; 95% CI: 46.1, 64.0). In controlled and uncontrolled portions of the studies with a median follow‑up of approximately 4&nbsp;years, the incidence per 100&nbsp;subject‑years of upper respiratory tract infections was 34.9&nbsp;events; 95% CI: 33.8, 36.0 for golimumab treated patients.</p><p><u>&nbsp;</u></p><p>In the controlled period of pivotal trials, infections were observed in 23.0% of golimumab‑treated patients (incidence per 100&nbsp;subject‑years: 132.0; 95% CI: 123.3, 141.1)<strong> </strong>compared with 20.2% of control patients (incidence per 100&nbsp;subject‑years: 122.3; 95% CI: 109.5, 136.2). In controlled and uncontrolled portions of the trials with a median follow‑up of approximately 4&nbsp;years, the incidence per 100&nbsp;subject‑years of infections was 81.1&nbsp;events; 95% CI: 79.5, 82.8 for golimumab treated patients.</p><p>&nbsp;</p><p>In the controlled period of RA, PsA, AS, and nr‑Axial SpA trials, serious infections were observed in 1.2% of golimumab‑treated patients and 1.2% of control‑treated patients. The incidence of serious infections per 100&nbsp;subject‑years of follow‑up in the controlled period of RA, PsA, AS, and nr‑Axial SpA trials was 7.3; 95% CI: 4.6, 11.1 for the golimumab 100&nbsp;mg group, 2.9; 95% CI: 1.2, 6.0 for the golimumab 50&nbsp;mg group and 3.6; 95% CI: 1.5, 7.0 for the placebo group. In the controlled period of UC trials of golimumab induction, serious infections were observed in 0.8% of golimumab-treated patients compared with 1.5% of control-treated patients. Serious infections observed in golimumab‑treated patients included tuberculosis, bacterial infections including sepsis and pneumonia, invasive fungal infections and other opportunistic infections. Some of these infections have been fatal. In the controlled and uncontrolled portions of the pivotal trials with a median follow‑up of up to 3&nbsp;years, there was a greater incidence of serious infections, including opportunistic infections and TB in patients receiving golimumab 100&nbsp;mg compared with patients receiving golimumab 50&nbsp;mg. The incidence per 100&nbsp;subject‑years of all serious infections was 4.1; 95% CI: 3.6, 4.5, in patients receiving golimumab 100&nbsp;mg and 2.5; 95% CI: 2.0, 3.1, in patients receiving golimumab 50&nbsp;mg.</p><p>&nbsp;</p><p><em>Malignancies</em></p><p><em><u>Lymphoma</u></em></p><p>The incidence of lymphoma in golimumab-treated patients during the pivotal trials was higher than expected in the general population. In the controlled and uncontrolled portions of these trials with a median follow‑up of up to 3&nbsp;years, a greater incidence of lymphoma was observed in patients receiving golimumab 100&nbsp;mg compared with patients receiving golimumab 50&nbsp;mg. Lymphoma was diagnosed in 11&nbsp;subjects (1 in the golimumab 50&nbsp;mg treatment groups and 10 in the golimumab 100&nbsp;mg treatment groups) with an incidence (95% CI) per 100&nbsp;subject‑years of follow-up of 0.03 (0.00, 0.15) and 0.13 (0.06, 0.24) events for golimumab 50&nbsp;mg and 100&nbsp;mg respectively and 0.00 (0.00, 0.57) events for the placebo. The majority of lymphomas occurred in study GO‑AFTER, which enrolled patients previously exposed to anti‑TNF agents who had longer disease duration and more refractory disease (see&nbsp;section 4.4).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Malignancies other than lymphoma</u></em></p><p>In the controlled periods of pivotal trials and through approximately 4&nbsp;years of follow‑up, the incidence of non‑lymphoma malignancies (excluding non‑melanoma skin cancer) was similar between the golimumab and the control groups. Through approximately 4&nbsp;years of follow-up, the incidence of non-lymphoma malignancies (excluding non-melanoma skin cancer) was similar to the general population.</p><p>&nbsp;</p><p>In the controlled and uncontrolled periods of pivotal trials with a median follow-up of up to 3&nbsp;years, non-melanoma skin cancer was diagnosed in 5 placebo-treated, 10 golimumab 50&nbsp;mg-treated and 31 golimumab 100&nbsp;mg-treated subjects with an incidence (95% CI) per 100&nbsp;subject‑years of follow-up of 0.36 (0.26, 0.49) for combined golimumab and 0.87 (0.28, 2.04) for placebo.</p><p>&nbsp;</p><p>In the controlled and uncontrolled period of pivotal trials with a median follow-up of up to 3&nbsp;years, malignancies besides melanoma, non-melanoma skin cancer and lymphoma were diagnosed in 5 placebo-treated, 21 golimumab 50&nbsp;mg-treated and 34 golimumab 100&nbsp;mg-treated subjects with an incidence (95% CI) per 100&nbsp;subject‑years of follow‑up of 0.48 (0.36, 0.62) for combined golimumab and 0.87 (0.28, 2.04) for placebo (see&nbsp;section&nbsp;4.4).</p><p><u>&nbsp;</u></p><p><em><u>Cases reported in clinical studies in asthma</u></em></p><p>In an exploratory clinical study, patients with severe persistent asthma received a golimumab loading dose (150% of the assigned treatment dose) subcutaneously at week&nbsp;0 followed by golimumab 200&nbsp;mg, golimumab 100&nbsp;mg or golimumab 50&nbsp;mg every 4&nbsp;weeks subcutaneously through week&nbsp;52. Eight malignancies in the combined golimumab treatment group (n&nbsp;=&nbsp;230) and none in the placebo treatment group (n&nbsp;=&nbsp;79) were reported. Lymphoma was reported in 1&nbsp;patient, non‑melanoma skin cancer in 2&nbsp;patients, and other malignancies in 5&nbsp;patients. There was no specific clustering of any type of malignancy.</p><p>&nbsp;</p><p>During the placebo‑controlled portion of the study, the incidence (95% CI) of all malignancies per 100&nbsp;subject‑years of follow‑up was 3.19 (1.38, 6.28) in the golimumab group. In this study, the incidence (95% CI) per 100&nbsp;subject‑years of follow‑up in golimumab‑treated subjects was 0.40 (0.01, 2.20) for lymphoma, 0.79 (0.10, 2.86) for non‑melanoma skin cancers, and 1.99 (0.64, 4.63) for other malignancies. For placebo subjects, the incidence (95% CI) per 100&nbsp;subject‑years of follow‑up of these malignancies was 0.00 (0.00, 2.94). The significance of this finding is unknown.</p><p>&nbsp;</p><p><em>Neurological events</em></p><p>In the controlled and uncontrolled periods of the pivotal trials with a median follow‑up of up to 3&nbsp;years, a greater incidence of demyelination was observed in patients receiving golimumab 100&nbsp;mg compared with patients receiving golimumab 50&nbsp;mg (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Liver enzyme elevations</em></p><p>In the controlled period of RA and PsA pivotal trials, mild ALT elevations (&gt;&nbsp;1 and &lt;&nbsp;3&nbsp;x&nbsp;upper limit of normal (ULN)) occurred in similar proportions of golimumab and control patients in the RA and PsA studies (22.1% to 27.4% of patients); in the AS and nr‑Axial SpA studies, more golimumab‑treated patients (26.9%) than control patients (10.6%) had mild ALT elevations. In the controlled and uncontrolled periods of the RA and PsA pivotal trials, with a median follow-up of approximately 5&nbsp;years, the incidence of mild ALT elevations was similar in golimumab‑treated and control patients in RA and PsA studies. In the controlled period of the UC pivotal trials of golimumab induction, mild ALT elevations (&gt;&nbsp;1 and &lt;&nbsp;3&nbsp;x&nbsp;ULN) occurred in similar proportions of golimumab-treated and control patients (8.0% to 6.9%, respectively). In controlled and uncontrolled periods of the UC pivotal trials with a median follow-up of approximately 2&nbsp;years, the proportion of patients with mild ALT elevations was 24.7% in patients receiving golimumab during the maintenance portion of the UC study.</p><p>&nbsp;</p><p>In the controlled period of RA and AS pivotal trials, ALT elevations &ge;&nbsp;5&nbsp;x&nbsp;ULN were uncommon and seen in more golimumab‑treated patients (0.4% to 0.9%) than control patients (0.0%). This trend was not observed in the PsA population. In the controlled and uncontrolled periods of RA, PsA and AS pivotal trials, with a median follow-up of 5&nbsp;years, the incidence of ALT elevations &ge;&nbsp;5&nbsp;x&nbsp;ULN was similar in both golimumab‑treated and control patients. In general these elevations were asymptomatic and the abnormalities decreased or resolved with either continuation or discontinuation of golimumab or modification of concomitant medicinal products. No cases were reported in the controlled and uncontrolled periods of the nr‑Axial SpA study (up to 1&nbsp;year). In the controlled periods of the pivotal UC trials, of golimumab induction, ALT elevations &ge;&nbsp;5&nbsp;x&nbsp;ULN occurred in similar proportions of golimumab-treated patients compared to placebo-treated patients (0.3% to 1.0%, respectively). In the controlled and uncontrolled periods of the pivotal UC trials with a median follow-up of approximately 2&nbsp;years, the proportion of patients with ALT elevations &ge;&nbsp;5&nbsp;x&nbsp;ULN was 0.8% in patients receiving golimumab during the maintenance portion of the UC study.</p><p>&nbsp;</p><p>Within the RA, PsA, AS, and nr‑Axial SpA pivotal trials, one patient in an RA trial with pre‑existing liver abnormalities and confounding medicinal products treated with golimumab developed non‑infectious fatal hepatitis with jaundice. The role of golimumab as a contributing or aggravation factor cannot be excluded.</p><p>&nbsp;</p><p><em>Injection site reactions</em></p><p>In the controlled periods of pivotal trials, 5.4% of golimumab‑treated patients had injection site reactions compared with 2.0% in control patients. The presence of antibodies to golimumab may increase the risk of injection site reactions. The majority of the injection site reactions were mild and moderate and the most frequent manifestation was injection site erythema. Injection site reactions generally did not necessitate discontinuation of the medicinal product.</p><p><u>&nbsp;</u></p><p>In controlled Phase IIb and/or III trials in RA, PsA, AS, nr‑Axial SpA, severe persistent asthma, and Phase II/III trials in UC, no patients treated with golimumab developed anaphylactic reactions.</p><p>&nbsp;</p><p><em>Autoimmune antibodies</em></p><p>In the controlled and uncontrolled periods of pivotal trials through 1&nbsp;year of follow-up, 3.5% of golimumab‑treated patients and 2.3% of control patients were newly ANA‑positive (at titres of 1:160 or greater). The frequency of anti‑dsDNA antibodies at 1&nbsp;year of follow-up in patients anti‑dsDNA negative at baseline was 1.1%.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses up to 10&nbsp;mg/kg intravenously have been administered in a clinical study without dose‑limiting toxicity. In case of an overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse effects and appropriate symptomatic treatment be instituted immediately.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, tumour necrosis factor alpha (TNF‑&alpha;) inhibitors, ATC code: L04AB06</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Golimumab is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNF‑&alpha;, which prevents the binding of TNF‑&alpha; to its receptors.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The binding of human TNF by golimumab was shown to neutralise TNF‑&alpha;‑induced cell‑surface expression of the adhesion molecules E‑selectin, vascular cell adhesion molecule (VCAM)‑1 and intercellular adhesion molecule (ICAM)‑1 by human endothelial cells. <em>In vitro</em>, TNF‑induced secretion of interleukin (IL)‑6, IL‑8 and granulocyte‑macrophage colony stimulating factor (GM‑CSF) by human endothelial cells was also inhibited by golimumab.</p><p>&nbsp;</p><p>Improvement in C‑reactive protein (CRP) levels were observed relative to placebo groups and treatment with Simponi resulted in significant reductions from baseline in serum levels of IL‑6, ICAM‑1, matrix‑metalloproteinase (MMP)‑3 and vascular endothelial growth factor (VEGF) compared to control treatment. In addition, levels of TNF‑a were reduced in RA and AS patients and levels of IL‑8 were reduced in PsA patients. These changes were observed at the first assessment (week&nbsp;4) after the initial Simponi administration and were generally maintained through week&nbsp;24.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p><u>&nbsp;</u></p><p><em>Rheumatoid arthritis</em></p><p>The efficacy of Simponi was demonstrated in three multi‑centre, randomised, double‑blind, placebo‑controlled studies in over 1500&nbsp;patients &ge;&nbsp;18&nbsp;years of age with moderately to severely active RA diagnosed according to American College of Rheumatology (ACR) criteria for at least 3&nbsp;months prior to screening. Patients had at least 4 swollen and 4 tender joints. Simponi or placebo were subcutaneously administered every 4&nbsp;weeks.</p><p>&nbsp;</p><p>GO‑FORWARD evaluated 444&nbsp;patients who had active RA despite a stable dose of at least 15&nbsp;mg/week of MTX and who had not been previously treated with an anti‑TNF agent. Patients were randomised to receive placebo + MTX, Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX, Simponi 100&nbsp;mg&nbsp;+&nbsp;MTX or Simponi 100&nbsp;mg&nbsp;+&nbsp;placebo. Patients receiving placebo&nbsp;+&nbsp;MTX were switched to Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX after week&nbsp;24. At week&nbsp;52, patients entered an open label long‑term extension.</p><p>&nbsp;</p><p>GO‑AFTER evaluated 445&nbsp;patients who were previously treated with one or more of the anti‑TNF agents adalimumab, etanercept, or infliximab. Patients were randomised to receive placebo, Simponi 50&nbsp;mg, or Simponi 100&nbsp;mg. Patients were allowed to continue concomitant DMARD therapy with MTX, sulfasalazine (SSZ), and/or hydroxychloroquine (HCQ) during the study. The stated reasons for discontinuation of prior anti TNF therapies were lack of efficacy (58%), intolerance (13%), and/or reasons other than safety or efficacy (29%, mostly for financial reasons).</p><p><u>&nbsp;</u></p><p>GO‑BEFORE evaluated 637&nbsp;patients with active RA who were MTX‑na&iuml;ve and had not previously been treated with an anti‑TNF agent. Patients were randomised to receive placebo&nbsp;+&nbsp;MTX, Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX, Simponi 100&nbsp;mg&nbsp;+&nbsp;MTX or Simponi 100&nbsp;mg&nbsp;+&nbsp;placebo. At week&nbsp;52, patients entered an open label long‑term extension in which patients receiving placebo&nbsp;+&nbsp;MTX who had at least 1 tender or swollen joint were switched to Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX.</p><p><u>&nbsp;</u></p><p>In GO‑FORWARD, the (co‑)primary endpoints were the percentage of patients achieving an ACR&nbsp;20&nbsp;response at week&nbsp;14 and the improvement from baseline in Health Assessment Questionnaire (HAQ) at week&nbsp;24. In GO‑AFTER, the primary endpoint was the percentage of patients achieving an ACR&nbsp;20&nbsp;response at week&nbsp;14. In GO‑BEFORE, the co‑primary endpoints were the percentage of patients achieving ACR&nbsp;50&nbsp;response at week&nbsp;24 and the change from baseline in the van der Heijde‑modified Sharp (vdH‑S) score at week&nbsp;52. In addition to the primary endpoint(s), additional assessments of the impact of Simponi treatment on the signs and symptoms of arthritis, radiographic response, physical function and health‑related quality of life were performed.</p><p>&nbsp;</p><p>In general, no clinically meaningful differences in measures of efficacy were observed between the Simponi 50&nbsp;mg and 100&nbsp;mg dosing regimens with concomitant MTX, through week&nbsp;104 in GO‑FORWARD and GO‑BEFORE and through week&nbsp;24 in GO‑AFTER. In each of the RA studies by study design, patients in the long‑term extension may have switched between the 50&nbsp;mg and 100&nbsp;mg Simponi doses at the discretion of the study physician.</p><p>&nbsp;</p><p><em><u>Signs and symptoms</u></em></p><p>Key ACR results for the Simponi 50&nbsp;mg dose at weeks&nbsp;14, 24 and 52 for GO‑FORWARD, GO‑AFTER and GO‑BEFORE are shown in Table&nbsp;2 and are described below. Responses were observed at the first assessment (week&nbsp;4) after the initial Simponi administration.</p><p>&nbsp;</p><p>In GO‑FORWARD, among 89&nbsp;subjects randomised to Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX, 48 were still on this treatment at week&nbsp;104. Among those, 40, 33 and 24&nbsp;patients had ACR&nbsp;20/50/70&nbsp;response, respectively at week&nbsp;104. Among patients remaining in the study and treated with Simponi, similar rates of ACR&nbsp;20/50/70 response was observed from week&nbsp;104 through week&nbsp;256.</p><p>&nbsp;</p><p>In GO‑AFTER, the percentage of patients achieving an ACR&nbsp;20 response was greater for patients receiving Simponi than for patients receiving placebo regardless of the reason reported for discontinuation of one or more prior anti‑TNF therapies.</p><p>&nbsp;</p><p><strong>Table&nbsp;2</strong></p><p><strong>Key efficacy outcomes from the controlled portions of GO‑FORWARD, GO‑AFTER and GO‑BEFORE.</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>GO‑FORWARD</p><p>Active RA despite MTX</p></td><td colspan="2" style="vertical-align:top"><p>GO‑AFTER</p><p>Active RA, previously treated with one or more anti‑TNF agent(s)</p></td><td colspan="2" style="vertical-align:top"><p>GO‑BEFORE</p><p>Active RA, MTX Na&iuml;ve</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Placebo</p><p>+</p><p>MTX</p></td><td style="vertical-align:bottom"><p>Simponi</p><p>50&nbsp;mg</p><p>+</p><p>MTX</p></td><td style="vertical-align:bottom"><p>Placebo</p></td><td style="vertical-align:bottom"><p>Simponi</p><p>50&nbsp;mg</p></td><td style="vertical-align:bottom"><p>Placebo</p><p>+</p><p>MTX</p></td><td style="vertical-align:bottom"><p>Simponi</p><p>50&nbsp;mg</p><p>+</p><p>MTX</p></td></tr><tr><td style="vertical-align:top"><p>n<sup>a</sup></p></td><td style="vertical-align:top"><p>133</p></td><td style="vertical-align:top"><p>89</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>147</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>159</p></td></tr><tr><td colspan="7"><p><strong>Responders, % of patients</strong></p></td></tr><tr><td colspan="7"><p><strong>ACR&nbsp;20</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;14</p></td><td style="vertical-align:top"><p><strong>33%</strong></p></td><td style="vertical-align:top"><p><strong>55%*</strong></p></td><td style="vertical-align:top"><p><strong>18%</strong></p></td><td style="vertical-align:top"><p><strong>35%*</strong></p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;24</p></td><td style="vertical-align:top"><p>28%</p></td><td style="vertical-align:top"><p>60%*</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>31% p&nbsp;=&nbsp;0.002</p></td><td style="vertical-align:top"><p>49%</p></td><td style="vertical-align:top"><p>62%</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>52%</p></td><td style="vertical-align:top"><p>60%</p></td></tr><tr><td colspan="7"><p><strong>ACR&nbsp;50</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;14</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>35%*</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>15% p&nbsp;=&nbsp;0.021</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;24</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>37%*</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>16%*</p></td><td style="vertical-align:top"><p><strong>29%</strong></p></td><td style="vertical-align:top"><p><strong>40%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>36%</p></td><td style="vertical-align:top"><p>42%</p></td></tr><tr><td colspan="7"><p><strong>ACR&nbsp;70</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;14</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>14% p&nbsp;=&nbsp;0.008</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>10%</p><p>p&nbsp;=&nbsp;0.005</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;24</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>20%*</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>9% p&nbsp;=&nbsp;0.009</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>24%</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>22%</p></td><td style="vertical-align:top"><p>28%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp; n reflects randomised patients; actual number of patients evaluable for each endpoint may vary by timepoint.</p><p>*&nbsp;&nbsp;&nbsp; p&nbsp;&le;&nbsp;0.001</p><p>NA: Not Applicable</p></td></tr></tbody></table><p>&nbsp;</p><p>In GO‑BEFORE the primary analysis in patients with moderate to severe rheumatoid arthritis (combined Simponi 50 and 100&nbsp;mg&nbsp;+&nbsp;MTX groups vs MTX alone for ACR50) was not statistically significant at week&nbsp;24 (p&nbsp;=&nbsp;0.053). At week&nbsp;52 in the overall population, the percentage of patients in the Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX group who achieved an ACR response was generally higher but not significantly different when compared with MTX alone (see Table&nbsp;2). Additional analyses were performed in subsets representative of the indicated population of patients with severe, active and progressive RA. A generally greater effect of Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX versus MTX alone was demonstrated in the indicated population compared with the overall population.</p><p>&nbsp;</p><p>In GO‑FORWARD and GO‑AFTER, clinically meaningful and statistically significant responses in Disease Activity Scale (DAS)28 were observed at each prespecified time point, at week&nbsp;14 and at week&nbsp;24 (p&nbsp;&le;&nbsp;0.001). Among patients who remained on the Simponi treatment to which they were randomised at study start, DAS28&nbsp;responses were maintained through week&nbsp;104. Among patients remaining in the study and treated with Simponi, DAS28 responses were similar from week&nbsp;104 through week&nbsp;256.</p><p>&nbsp;</p><p>In GO‑BEFORE, major clinical response, defined as the maintenance of an ACR&nbsp;70&nbsp;response over a continuous 6‑month period, was measured. At week&nbsp;52, 15% of patients in the Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX group achieved a major clinical response compared with 7% of patients in the placebo&nbsp;+&nbsp;MTX group (p&nbsp;=&nbsp;0.018). Among 159&nbsp;subjects randomised to Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX, 96 were still on this treatment at week&nbsp;104. Among those, 85, 66 and 53&nbsp;patients had ACR&nbsp;20/50/70&nbsp;response, respectively, at week&nbsp;104. Among patients remaining in the study and treated with Simponi, similar rates of ACR&nbsp;20/50/70 response were observed from week&nbsp;104 through week&nbsp;256.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Radiographic response:</u></em></p><p>In GO‑BEFORE the change from baseline in the vdH‑S score, a composite score of structural damage that radiographically measures the number and size of joint erosions and the degree of joint space narrowing in hands/wrists and feet, was used to assess the degree of structural damage. Key results for the Simponi 50&nbsp;mg dose at week&nbsp;52 are presented in Table&nbsp;3.</p><p><em><u>&nbsp;</u></em></p><p>The number of patients with no new erosions or a change from baseline in total vdH‑S Score &le;&nbsp;0 was significantly higher in the Simponi treatment group than in the control group (p&nbsp;=&nbsp;0.003). The radiographic effects observed at week&nbsp;52 were maintained through week&nbsp;104. Among patients remaining in the study and treated with Simponi, radiographic effects were similar from week&nbsp;104 through week&nbsp;256.</p><p>&nbsp;</p><p><strong>Table&nbsp;3</strong></p><p><strong>Radiographic mean (SD) changes from baseline in total vdH‑S score at week&nbsp;52 in the overall population of </strong><strong>GO‑BEFORE</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:514px"><tbody><tr><td><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Placebo&nbsp;+&nbsp;MTX</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Simponi 50&nbsp;mg&nbsp;+&nbsp;MTX</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>n<strong><sup> a</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>160</strong></p></td><td style="vertical-align:bottom"><p><strong>159</strong></p></td></tr><tr><td colspan="3"><p><strong>Total Score </strong></p></td></tr><tr><td><p>Baseline</p></td><td><p>19.7 (35.4)</p></td><td style="vertical-align:bottom"><p>18.7 (32.4)</p></td></tr><tr><td><p>Change from baseline</p></td><td style="vertical-align:bottom"><p>1.4 (4.6)</p></td><td style="vertical-align:bottom"><p>0.7 (5.2)<sup>*</sup><sup> </sup></p></td></tr><tr><td colspan="3"><p><strong>Erosion Score</strong></p></td></tr><tr><td><p>Baseline</p></td><td style="vertical-align:bottom"><p>11.3 (18.6)</p></td><td style="vertical-align:bottom"><p>10.8 (17.4)</p></td></tr><tr><td><p>Change from baseline</p></td><td style="vertical-align:bottom"><p>0.7 (2.8)</p></td><td style="vertical-align:bottom"><p>0.5 (2.1)</p></td></tr><tr><td colspan="3"><p><strong>JSN Score</strong></p></td></tr><tr><td><p>Baseline</p></td><td style="vertical-align:bottom"><p>8.4 (17.8)</p></td><td style="vertical-align:bottom"><p>7.9 (16.1)</p></td></tr><tr><td><p>Change from baseline</p></td><td style="vertical-align:bottom"><p>0.6 (2.3)</p></td><td style="vertical-align:bottom"><p>0.2 (2.0)<sup>**</sup></p></td></tr><tr><td colspan="3"><p><sup>a</sup>&nbsp;&nbsp;&nbsp; n reflects randomised patients</p><p>*&nbsp;&nbsp;&nbsp; p&nbsp;=&nbsp;0.015</p><p>**&nbsp; p&nbsp;=&nbsp;0.044</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><em><u>Physical function and health‑related quality of life</u></em></p><p>Physical function and disability were assessed as a separate endpoint in GO‑FORWARD and GO‑AFTER using the disability index of the HAQ DI. In these studies, Simponi demonstrated clinically meaningful and statistically significant improvement in HAQ DI from baseline versus control at week&nbsp;24. Among patients who remained on the Simponi treatment to which they were randomised at study start, improvement in HAQ DI was maintained through week&nbsp;104. Among patients remaining in the study and treated with Simponi, improvement in HAQ DI was similar from week&nbsp;104 through week&nbsp;256.</p><p>&nbsp;</p><p>In GO‑FORWARD clinically meaningful and statistically significant improvements were demonstrated in health‑related quality of life as measured by the physical component score of the SF‑36 in patients treated with Simponi versus placebo at week&nbsp;24. Among patients who remained on the Simponi treatment to which they were randomised at study start, improvement of the SF‑36 physical component was maintained through week&nbsp;104. Among patients remaining in the study and treated with Simponi, improvement of the SF‑36 physical component was similar from week&nbsp;104 through week&nbsp;256. In GO‑FORWARD and GO‑AFTER, statistically significant improvements were observed in fatigue as measured by functional assessment of chronic illness therapy‑fatigue scale (FACIT‑F).</p><p>&nbsp;</p><p><em>Psoriatic arthritis</em></p><p>The safety and efficacy of Simponi were evaluated in a multi‑centre, randomised, double‑blind, placebo‑controlled study (GO‑REVEAL) in 405&nbsp;adult patients with active PsA (&ge;&nbsp;3 swollen joints and &ge;&nbsp;3 tender joints) despite non‑steroidal anti‑inflammatory (NSAID) or DMARD therapy. Patients in this study had a diagnosis of PsA for at least 6&nbsp;months and had at least mild psoriatic disease. Patients with each sub‑type of psoriatic arthritis were enrolled, including polyarticular arthritis with no rheumatoid nodules (43%), asymmetric peripheral arthritis (30%), distal interphalangeal (DIP) joint arthritis (15%), spondylitis with peripheral arthritis (11%), and arthritis mutilans (1%). Previous treatment with an anti‑TNF agent was not allowed. Simponi or placebo were administered subcutaneously every 4&nbsp;weeks. Patients were randomly assigned to placebo, Simponi 50&nbsp;mg, or Simponi 100&nbsp;mg. Patients receiving placebo were switched to Simponi 50&nbsp;mg after week&nbsp;24. Patients entered an open label long‑term extension at week&nbsp;52. Approximately forty‑eight percent of patients continued on stable doses of methotrexate (&le;&nbsp;25&nbsp;mg/week). The co‑primary endpoints were the percentage of patients achieving ACR&nbsp;20&nbsp;response at week&nbsp;14 and change from baseline in total PsA modified vdH‑S score at week&nbsp;24.</p><p>&nbsp;</p><p>In general, no clinically meaningful differences in measures of efficacy were observed between the Simponi 50&nbsp;mg and 100&nbsp;mg dosing regimens through week&nbsp;104. By study design, patients in the long‑term extension may have switched between the 50&nbsp;mg and 100&nbsp;mg Simponi doses at the discretion of the study physician.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Signs and symptoms</u></em></p><p>Key results for the 50&nbsp;mg dose at weeks&nbsp;14 and 24 are shown in table&nbsp;4 and described below.</p><p>&nbsp;</p><p><strong>Table&nbsp;4</strong></p><p><strong>Key efficacy outcomes from GO‑REVEAL</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:488px"><tbody><tr><td><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Placebo</p></td><td style="vertical-align:bottom"><p>Simponi</p><p>50&nbsp;mg*</p></td></tr><tr><td><p>n<sup>a</sup></p></td><td><p>113</p></td><td><p>146</p></td></tr><tr><td colspan="3"><p><strong>Responders, % of patients</strong></p></td></tr><tr><td><p><strong>ACR&nbsp;20</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Week&nbsp;14</p></td><td><p><strong>9%</strong></p></td><td><p><strong>51%</strong></p></td></tr><tr><td><p>Week&nbsp;24</p></td><td><p>12%</p></td><td><p>52%</p></td></tr><tr><td><p><strong>ACR&nbsp;50</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Week&nbsp;14</p></td><td><p>2%</p></td><td><p>30%</p></td></tr><tr><td><p>Week&nbsp;24</p></td><td><p>4%</p></td><td><p>32%</p></td></tr><tr><td><p><strong>ACR&nbsp;70</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Week&nbsp;14</p></td><td><p>1%</p></td><td><p>12%</p></td></tr><tr><td><p>Week&nbsp;24</p></td><td><p>1%</p></td><td><p>19%</p></td></tr><tr><td><p><strong>PASI<sup>b</sup> 75<sup>c</sup></strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Week&nbsp;14</p></td><td><p>3%</p></td><td style="vertical-align:bottom"><p>40%</p></td></tr><tr><td><p>Week&nbsp;24</p></td><td><p>1%</p></td><td style="vertical-align:bottom"><p>56%</p></td></tr><tr><td colspan="3"><p>*&nbsp;&nbsp;&nbsp; p&nbsp;&lt;&nbsp;0.05 for all comparisons;</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp; n reflects randomised patients; actual number of patients evaluable for each endpoint may vary by timepoint</p><p><sup>b</sup><em>&nbsp;&nbsp;&nbsp; </em><em>Psoriasis Area and Severity Index</em></p><p><sup>c</sup><em>&nbsp;&nbsp;&nbsp; </em>Based on the subset of patients with &ge;&nbsp;3% BSA involvement at baseline, 79&nbsp;patients (69.9%) in the placebo group and 109 (74.3%) in the Simponi 50&nbsp;mg group.</p></td></tr></tbody></table><p>&nbsp;</p><p>Responses were observed at the first assessment (week&nbsp;4) after the initial Simponi administration. Similar ACR&nbsp;20&nbsp;responses at week&nbsp;14 were observed in patients with polyarticular arthritis with no rheumatoid nodules and asymmetric peripheral arthritis PsA subtypes. The number of patients with other PsA subtypes was too small to allow meaningful assessment. Responses observed in the Simponi treated groups were similar in patients receiving and not receiving concomitant MTX. Among 146&nbsp;patients randomised to Simponi 50&nbsp;mg, 70 were still on this treatment at week&nbsp;104. Of these 70&nbsp;patients, 64, 46 and 31&nbsp;patients had an ACR&nbsp;20/50/70&nbsp;response, respectively. Among patients remaining in the study and treated with Simponi, similar rates of ACR&nbsp;20/50/70 response was observed from week&nbsp;104 through week&nbsp;256.</p><p>&nbsp;</p><p>Statistically significant responses in DAS28 were also observed at weeks&nbsp;14 and 24 (p&nbsp;&lt;&nbsp;0.05).</p><p>&nbsp;</p><p>At week&nbsp;24 improvements in parameters of peripheral activity characteristic of psoriatic arthritis (e.g. number of swollen joints, number of painful/tender joints, dactylitis and enthesitis) were seen in the Simponi‑treated patients. Simponi treatment resulted in significant improvement in physical function as assessed by HAQ DI, as well as significant improvements in health‑related quality of life as measured by the physical and mental component summary scores of the SF‑36. Among patients who remained on the Simponi treatment to which they were randomised at study start, DAS28 and HAQ DI responses were maintained through week&nbsp;104. Among patients remaining in the study and treated with Simponi, DAS28 and HAQ DI responses were similar from week&nbsp;104 through week&nbsp;256.</p><p>&nbsp;</p><p><em><u>Radiographic response:</u></em></p><p>Structural damage in both hands and feet was assessed radiographically by the change from baseline in the vdH‑S score, modified for PsA by addition of hand distal interphalangeal (DIP) joints.</p><p>&nbsp;</p><p>Simponi 50&nbsp;mg treatment reduced the rate of progression of peripheral joint damage compared with placebo treatment at week&nbsp;24 as measured by change from baseline in total modified vdH‑S Score (mean&nbsp;&plusmn;&nbsp;SD score was 0.27&nbsp;&plusmn;&nbsp;1.3 in the placebo group compared with ‑0.16&nbsp;&plusmn;&nbsp;1.3 in the Simponi group; p&nbsp;=&nbsp;0.011). Out of 146&nbsp;patients who were randomised to Simponi 50&nbsp;mg, 52&nbsp;week X‑ray data were available for 126&nbsp;patients, of whom 77% showed no progression compared to baseline. At week&nbsp;104, X‑ray data were available for 114&nbsp;patients, and 77% showed no progression from baseline. Among patients remaining in the study and treated with Simponi, similar rates of patients showed no progression from baseline from week&nbsp;104 through week&nbsp;256.</p><p><u>&nbsp;</u></p><p><em><u>Axial spondyloarthritis</u></em></p><p><em>Ankylosing spondylitis</em></p><p>The safety and efficacy of Simponi were evaluated in a multi‑centre, randomised, double‑blind, placebo‑controlled study (GO‑RAISE) in 356&nbsp;adult patients with active ankylosing spondylitis (defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) &ge;&nbsp;4 and a VAS for total back pain of &ge;&nbsp;4, on a scale of 0 to 10&nbsp;cm). Patients enrolled in this study had active disease despite current or previous NSAID or DMARD therapy and had not previously been treated with anti‑TNF therapy. Simponi or placebo were administered subcutaneously every 4&nbsp;weeks. Patients were randomly assigned to placebo, Simponi 50&nbsp;mg and Simponi 100&nbsp;mg and were allowed to continue concomitant DMARD therapy (MTX, SSZ and/or HCQ). The primary endpoint was the percentage of patients achieving Ankylosing Spondylitis Assessment Study Group (ASAS)&nbsp;20&nbsp;response at week&nbsp;14. Placebo‑controlled efficacy data were collected and analysed through week&nbsp;24.</p><p>&nbsp;</p><p>Key results for the 50&nbsp;mg dose are shown in Table&nbsp;5 and described below. In general, no clinically meaningful differences in measures of efficacy were observed between the Simponi 50&nbsp;mg and 100&nbsp;mg dosing regimens through week&nbsp;24. By study design, patients in the long-term extension may have switched bewtween the 50&nbsp;mg and 100&nbsp;mg Simponi doses at the discretion of the study physician.</p><p>&nbsp;</p><p><strong>Table&nbsp;5</strong></p><p><strong>Key efficacy outcomes from GO‑RAISE.</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:535px"><tbody><tr><td><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Placebo</p></td><td style="vertical-align:bottom"><p>Simponi</p><p>50&nbsp;mg*</p></td></tr><tr><td><p>n<sup>a</sup></p></td><td><p>78</p></td><td><p>138</p></td></tr><tr><td colspan="3"><p><strong>Responders, % of patients</strong></p></td></tr><tr><td colspan="3"><p><strong>ASAS&nbsp;20</strong></p></td></tr><tr><td><p>Week&nbsp;14</p></td><td><p><strong>22% </strong></p></td><td><p><strong>59% </strong></p></td></tr><tr><td><p>Week&nbsp;24</p></td><td><p>23%</p></td><td><p>56%</p></td></tr><tr><td colspan="3"><p><strong>ASAS&nbsp;40</strong></p></td></tr><tr><td><p>Week&nbsp;14</p></td><td><p>15%</p></td><td><p>45%</p></td></tr><tr><td><p>Week&nbsp;24</p></td><td><p>15%</p></td><td><p>44%</p></td></tr><tr><td colspan="3"><p><strong>ASAS&nbsp;5/6</strong></p></td></tr><tr><td><p>Week&nbsp;14</p></td><td><p>8%</p></td><td><p>50%</p></td></tr><tr><td><p>Week&nbsp;24</p></td><td><p>13%</p></td><td><p>49%</p></td></tr><tr><td colspan="3"><p>*&nbsp;&nbsp;&nbsp; p&nbsp;&le;&nbsp;0.001 for all comparisons</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp; n reflects randomised patients; actual number of patients evaluable for each endpoint may vary by timepoint</p></td></tr></tbody></table><p>&nbsp;</p><p>Among patients remaining in the study and treated with Simponi, the proportion of patients with an ASAS&nbsp;20 and ASAS&nbsp;40 response were similar from week&nbsp;24 through week&nbsp;256.</p><p>&nbsp;</p><p>Statistically significant responses in BASDAI&nbsp;50, 70 and 90 (p&nbsp;&le;&nbsp;0.017) were also seen at weeks&nbsp;14 and 24. Improvements in key measures of disease activity were observed at the first assessment (week&nbsp;4) after the initial Simponi administration and were maintained through week&nbsp;24. Among patients remaining in the study and treated with Simponi, similar rates of change from baseline in BASDAI were observed from week&nbsp;24 through week&nbsp;256. Consistent efficacy was seen in patients regardless of use of DMARDs (MTX, sulfasalazine and/or hydroxychloroquine), HLA‑B27 antigen status or baseline CRP levels as assessed by ASAS&nbsp;20&nbsp;responses at week&nbsp;14.</p><p>&nbsp;</p><p>Simponi treatment resulted in significant improvements in physical function as assessed by changes from baseline in BASFI at weeks&nbsp;14 and 24. Health‑related quality of life as measured by the physical component score of the SF‑36 was also improved significantly at weeks&nbsp;14 and 24. Among patients remaining in the study and treated with Simponi, improvements in physical function and health‑related quality of life were similar from week&nbsp;24 through week&nbsp;256.</p><p>&nbsp;</p><p><em>Non‑radiographic axial spondyloarthritis</em></p><p>The safety and efficacy of Simponi were evaluated in a multi‑centre, randomised, double‑blind, placebo‑controlled study (GO‑AHEAD) in 197 adult patients with severe active nr‑Axial SpA (defined as those patients meeting the ASAS classification criteria of axial spondyloarthritis but did not meet the modified New York criteria for AS). Patients enrolled in this study had active disease (defined as a BASDAI &ge;&nbsp;4 and a Visual Analogue Scale (VAS) for total back pain of &ge;&nbsp;4, each on a scale of 0‑10&nbsp;cm) despite current or previous NSAID therapy and had not previously been treated with any biological agents including anti‑TNF therapy. Patients were randomly assigned to placebo or Simponi 50&nbsp;mg administered subcutaneously every 4&nbsp;weeks. At week&nbsp;16, patients entered an open label period in which all patients received Simponi 50&nbsp;mg administered subcutaneously every 4&nbsp;weeks through week&nbsp;48 with efficacy assessments performed through week&nbsp;52 and safety follow‑up through week&nbsp;60. Approximately 93% of patients who were receiving Simponi at the beginning of the open‑label extension (week&nbsp;16) remained on treatment through the end of the study (week&nbsp;52). Analyses were performed on both the All Treated (AT, N&nbsp;=&nbsp;197) and Objective Signs of Inflammation (OSI, N&nbsp;=&nbsp;158, defined by elevated CRP and/or evidence of sacroiliitis on MRI at baseline) populations. Placebo‑controlled efficacy data were collected and analysed through week&nbsp;16. The primary endpoint was the proportion of patients achieving ASAS&nbsp;20 response at week&nbsp;16. Key results are shown in Table&nbsp;6 and described below.</p><p>&nbsp;</p><p><strong>Table&nbsp;6</strong></p><p><strong>Key efficacy outcomes from GO-AHEAD at week&nbsp;16</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Improvements in signs and symptoms</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>All treated population (AT)</p></td><td colspan="2" style="vertical-align:bottom"><p>Objective signs of inflammation population (OSI)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Simponi 50&nbsp;mg</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Simponi 50&nbsp;mg</p></td></tr><tr><td><p>n<sup>a</sup></p></td><td><p>100</p></td><td><p>97</p></td><td><p>80</p></td><td><p>78</p></td></tr><tr><td colspan="5"><p><strong>Responders, % of patients</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS&nbsp;20</p></td><td style="vertical-align:bottom"><p>40%</p></td><td style="vertical-align:bottom"><p>71%**</p></td><td style="vertical-align:bottom"><p>38%</p></td><td style="vertical-align:bottom"><p>77%**</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS&nbsp;40</p></td><td style="vertical-align:bottom"><p>23%</p></td><td style="vertical-align:bottom"><p>57%**</p></td><td style="vertical-align:bottom"><p>23%</p></td><td style="vertical-align:bottom"><p>60%**</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS&nbsp;5/6<sup> </sup></p></td><td style="vertical-align:bottom"><p>23%</p></td><td style="vertical-align:bottom"><p>54%**</p></td><td style="vertical-align:bottom"><p>23%</p></td><td style="vertical-align:bottom"><p>63%**</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS&nbsp;Partial Remission</p></td><td style="vertical-align:bottom"><p>18%</p></td><td style="vertical-align:bottom"><p>33%*</p></td><td style="vertical-align:bottom"><p>19%</p></td><td style="vertical-align:bottom"><p>35%*</p></td></tr><tr><td style="vertical-align:bottom"><p>ASDAS-C<sup> b</sup> &lt;&nbsp;1.3<sup> </sup></p></td><td style="vertical-align:bottom"><p>13%</p></td><td style="vertical-align:bottom"><p>33%*</p></td><td style="vertical-align:bottom"><p>16%</p></td><td style="vertical-align:bottom"><p>35%*</p></td></tr><tr><td style="vertical-align:bottom"><p>BASDAI&nbsp;50</p></td><td style="vertical-align:bottom"><p>30%</p></td><td style="vertical-align:bottom"><p>58%**</p></td><td style="vertical-align:bottom"><p>29%</p></td><td style="vertical-align:bottom"><p>59%**</p></td></tr><tr><td colspan="5" style="vertical-align:bottom"><p><strong>Inhibition of inflammation in sacroiliac (SI) joints as measured by MRI</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Placebo</p></td><td style="vertical-align:bottom"><p>Simponi 50&nbsp;mg</p></td><td style="vertical-align:bottom"><p>Placebo</p></td><td style="vertical-align:bottom"><p>Simponi 50&nbsp;mg</p></td></tr><tr><td style="vertical-align:bottom"><p>n <sup>C</sup></p></td><td style="vertical-align:bottom"><p>87</p></td><td style="vertical-align:bottom"><p>74</p></td><td style="vertical-align:bottom"><p>69</p></td><td style="vertical-align:bottom"><p>61</p></td></tr><tr><td style="vertical-align:bottom"><p>Mean change in SPARCC<sup>d</sup><sup> </sup>MRI</p><p>sacroiliac joint score</p></td><td style="vertical-align:bottom"><p>‑0.9</p></td><td style="vertical-align:bottom"><p>‑5.3**</p></td><td style="vertical-align:bottom"><p>‑1.2</p></td><td style="vertical-align:bottom"><p>‑6.4**</p></td></tr><tr><td colspan="5" style="vertical-align:bottom"><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>n reflects randomised and treated patients</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Ankylosing Spondylitis Disease Activity Score C-Reactive Protein (AT‑Placebo, N&nbsp;=&nbsp;90; AT‑Simponi 50&nbsp;mg, N&nbsp;=&nbsp;88; OSI‑Placebo, N&nbsp;=&nbsp;71; OSI‑Simponi 50&nbsp;mg, N&nbsp;=&nbsp;71)</p><p><sup>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>n reflects number of patients with baseline and week&nbsp;16 MRI data</p><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>SPARCC (Spondyloarthritis Research Consortium of Canada)</p><p>**&nbsp; p&nbsp;&lt;&nbsp;0.0001 for Simponi <em>vs</em> placebo comparisons</p><p>*&nbsp;&nbsp;&nbsp; p&nbsp;&lt;&nbsp;0.05 for Simponi <em>vs</em> placebo comparisons</p></td></tr></tbody></table><p>&nbsp;</p><p>Statistically significant improvements in signs and symptoms of severe active nr‑Axial SpA were demonstrated in patients treated with Simponi 50&nbsp;mg compared to placebo at week&nbsp;16 (Table&nbsp;6). Improvements were observed at the first assessment (week&nbsp;4) after the initial Simponi administration. SPARCC score as measured by MRI showed statistically significant reductions in SI joint inflammation at week&nbsp;16 in patients treated with Simponi 50&nbsp;mg compared to placebo (Table&nbsp;6). Pain as assessed by the Total Back Pain and Nocturnal Back Pain VAS, and disease activity as measured by ASDAS‑C also showed statistically significant improvement from baseline to week&nbsp;16 in patients treated with Simponi 50&nbsp;mg compared to placebo (p&nbsp;&lt;&nbsp;0.0001).</p><p>&nbsp;</p><p>Statistically significant improvements in spinal mobility as assessed by BASMI (Bath Ankylosing Spondylitis Metrology Index) and in physical function as assessed by the BASFI were demonstrated in Simponi 50&nbsp;mg‑treated patients as compared to placebo‑treated patients (p&nbsp;&lt;&nbsp;0.0001). Patients treated with Simponi experienced significantly more improvements in health‑related quality of life as assessed by ASQoL, EQ‑5D, and physical and mental components of SF‑36, and experienced significantly more improvements in productivity as assessed by greater reductions in overall work impairment and in activity impairment as assessed by the WPAI questionnaire than patients receiving placebo.</p><p>&nbsp;</p><p>For all of the endpoints described above, statistically significant results were also demonstrated in the OSI population at week&nbsp;16.</p><p>&nbsp;</p><p>In both the AT and OSI populations, the improvements in signs and symptoms, spinal mobility, physical function<em>, </em>quality of life, and productivity<em> </em>observed at week&nbsp;16 among patients treated with Simponi 50&nbsp;mg continued in those remaining in the study at week&nbsp;52.</p><p>&nbsp;</p><p><em>Ulcerative colitis</em></p><p>The efficacy of Simponi was evaluated in two randomised, double-blind, placebo-controlled clinical studies in adult patients.</p><p>&nbsp;</p><p>The induction study (PURSUIT-Induction) evaluated patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore &ge;&nbsp;2) who had an inadequate response to or failed to tolerate conventional therapies, or were corticosteroid dependent. In the dose confirming portion of the study, 761&nbsp;patients were randomised to receive either 400&nbsp;mg Simponi SC at week&nbsp;0 and 200&nbsp;mg at week&nbsp;2, 200&nbsp;mg Simponi SC at week&nbsp;0 and 100&nbsp;mg at week&nbsp;2, or placebo SC at weeks&nbsp;0 and 2. Concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted. The efficacy of Simponi through week&nbsp;6 was assessed in this study.</p><p>&nbsp;</p><p>The results of the maintenance study (PURSUIT-Maintenance) were based on evaluation of 456&nbsp;patients who achieved clinical response from previous induction with Simponi. Patients were randomised to receive Simponi 50&nbsp;mg, Simponi 100&nbsp;mg or placebo administered subcutaneously every 4&nbsp;weeks. Concomitant stable doses of oral aminosalicylates, and/or immunomodulatory agents were permitted. Corticosteroids were to be tapered at the start of the maintenance study. The efficacy of Simponi through week&nbsp;54 was assessed in this study. Patients who completed the maintenance study through week&nbsp;54 continued treatment in a study extension, with efficacy evaluated through week&nbsp;216. Efficacy evaluation in the study extension was based on changes in corticosteroid use, Physician&rsquo;s Global Assessment (PGA) of disease activity, and improvement in quality of life as measured by Inflammatory Bowel Disease Questionnaire (IBDQ).</p><p>&nbsp;</p><p><strong>Table&nbsp;7</strong></p><p><strong>Key efficacy outcomes from PURSUIT - Induction and PURSUIT - Maintenance</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:500px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>PURSUIT-Induction</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Placebo</strong></p><p>N&nbsp;=&nbsp;251</p></td><td colspan="2" style="vertical-align:top"><p><strong>Simponi</strong></p><p><strong>200/100&nbsp;mg</strong></p><p>N&nbsp;=&nbsp;253</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Percentage of patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>Patients in clinical response at week&nbsp;6<sup>a</sup></p></td><td style="vertical-align:top"><p>30%</p></td><td colspan="2" style="vertical-align:top"><p>51%**</p></td></tr><tr><td style="vertical-align:top"><p>Patients in clinical remission at week&nbsp;6<sup>b</sup></p></td><td style="vertical-align:top"><p>6%</p></td><td colspan="2" style="vertical-align:top"><p>18%**</p></td></tr><tr><td style="vertical-align:top"><p>Patients with mucosal healing at week&nbsp;6<sup>c</sup></p></td><td style="vertical-align:top"><p>29%</p></td><td colspan="2" style="vertical-align:top"><p>42%*</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>PURSUIT-Maintenance</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Placebo<sup>d</sup></strong></p><p>N&nbsp;=&nbsp;154</p></td><td style="vertical-align:top"><p><strong>Simponi</strong></p><p><strong>50&nbsp;mg</strong></p><p>N&nbsp;=&nbsp;151</p></td><td style="vertical-align:top"><p><strong>Simponi</strong></p><p><strong>100&nbsp;mg</strong></p><p>N&nbsp;=&nbsp;151</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Percentage of patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of response (Patients in clinical response through week&nbsp;54)<sup>e</sup></p></td><td><p>31%</p></td><td><p>47%*</p></td><td><p>50%**</p></td></tr><tr><td style="vertical-align:top"><p>Sustained remission (Patients in clinical remission at both week&nbsp;30 and week&nbsp;54)<sup>f</sup></p></td><td><p>16%</p></td><td><p>23%<sup>g</sup></p></td><td><p>28%*</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>N&nbsp;=&nbsp;number of patients</p><p>**&nbsp; p&nbsp;&le;&nbsp;0.001</p><p>*&nbsp;&nbsp;&nbsp; p&nbsp;&le;&nbsp;0.01</p><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>defined as a decrease from baseline in the Mayo score by &ge;&nbsp;30% and &ge;&nbsp;3 points, accompanied by a decrease in the rectal bleeding subscore of &ge;&nbsp;1 or a rectal bleeding subscore of 0 or 1.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Defined as a Mayo score &le;&nbsp;2 points, with no individual subscore &gt;&nbsp;1</p><p><sup>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Defined as 0 or 1 on the endoscopy subscore of the Mayo score.</p><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Simponi induction only.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Patients were assessed for UC disease activity by partial Mayo score every 4&nbsp;weeks (loss of response was confirmed by endoscopy). Therefore, a patient who maintained response was in a state of continuous clinical response at each evaluation through week&nbsp;54.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; A patient had to be in remission at both weeks&nbsp;30 and 54 (without demonstrating a loss of response at any time point through week&nbsp;54) to achieve durable remission.</p><p><sup>g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>In patients weighing less than 80&nbsp;kg, a greater proportion of patients who received 50&nbsp;mg maintenance therapy showed sustained clinical remission compared with those who received placebo.</p></td></tr></tbody></table><p>&nbsp;</p><p>More Simponi-treated patients demonstrated sustained mucosal healing (patients with mucosal healing at both week&nbsp;30 and week&nbsp;54) in the 50&nbsp;mg group (42%, nominal p&nbsp;&lt;&nbsp;0.05) and 100&nbsp;mg group (42%, p&nbsp;&lt;&nbsp;0.005) compared with patients in the placebo group (27%).</p><p>&nbsp;</p><p>Among the 54% of patients (247/456) who were receiving concomitant corticosteroids at the start of PURSUIT-Maintenance, the proportion of patients who maintained clinical response through week&nbsp;54 and were not receiving concomitant corticosteroids at week&nbsp;54 was greater in the 50&nbsp;mg group (38%, 30/78) and 100&nbsp;mg group (30%, 25/82) compared with the placebo group (21%, 18/87). The proportion of patients who eliminated corticosteroids by week&nbsp;54 was greater in the 50&nbsp;mg group (41%, 32/78) and 100&nbsp;mg group (33%, 27/82) compared with the placebo group (22%, 19/87). Among patients who entered the study extension, the proportion of subjects who remained corticosteroid free was generally maintained through week 216.</p><p>&nbsp;</p><p>At week&nbsp;6, Simponi significantly improved quality of life as measured by change from baseline in a disease specific measure, IBDQ (inflammatory bowel disease questionnaire). Among patients who received Simponi maintenance treatment, the improvement in quality of life as measured by IBDQ was maintained through week&nbsp;54.</p><p><u>&nbsp;</u></p><p>Approximately 63% of patients who were receiving Simponi at the beginning of the study extension (week&nbsp;56), remained on treatment through the end of the study (last golimumab administration at week&nbsp;212).</p><p><u>&nbsp;</u></p><p><u>Immunogenicity</u></p><p>Across the Phase III RA, PsA and AS studies through week&nbsp;52, antibodies to golimumab were detected in 5% (105/2062) of golimumab treated patients and, where tested, nearly all antibodies were neutralising <em>in vitro</em>. Similar rates were shown across rheumatologic indications. Treatment with concomitant MTX resulted in a lower proportion of patients with antibodies to golimumab than patients receiving golimumab without MTX (approximately 3% [41/1235] versus 8% [64/827], respectively).</p><p>&nbsp;</p><p>In nr‑Axial SpA, antibodies to golimumab were detected in 7%&nbsp;(14/193) of golimumab treated patients through week&nbsp;52.</p><p>&nbsp;</p><p>In the Phase II and III UC studies through week&nbsp;54, antibodies to golimumab were detected in 3%&nbsp;(26/946) of golimumab treated patients. Sixty-eight percent (21/31) of antibody-positive patients had neutralising antibodies <em>in vitro</em>. Treatment with concomitant immunomodulators (azathioprine, 6‑mercaptopurine and MTX) resulted in a lower proportion of patients with antibodies to golimumab than patients receiving golimumab without immunomodulators (1%&nbsp;(4/308) versus 3%&nbsp;(22/638), respectively). Of patients that continued in the study extension and had evaluable samples through week&nbsp;228, antibodies to golimumab were detected in 4% (23/604) of golimumab treated patients. Eighty-two percent (18/22) of antibody-positive patients had neutralizing antibodies <em>in vitro</em>.</p><p>&nbsp;</p><p>The presence of antibodies to golimumab may increase the risk of injection site reactions (see&nbsp;section&nbsp;4.4). The small number of patients positive for antibodies to golimumab limits the ability to draw definitive conclusions regarding the relationship between antibodies to golimumab and clinical efficacy or safety measures.</p><p>&nbsp;</p><p>Because immunogenicity analyses are product‑ and assay‑specific, comparison of antibody rates with those from other products is not appropriate.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Simponi in the paediatric population in ulcerative colitis (see&nbsp;section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em></p><p>Following a single subcutaneous administration of golimumab<strong> </strong>to healthy subjects or patients with RA, the median time to reach maximum serum concentrations (T<sub>max</sub>) ranged from 2 to 6&nbsp;days. A subcutaneous injection of 50&nbsp;mg golimumab to healthy subjects produced a mean &plusmn; standard deviation maximum serum concentration (C<sub>max</sub>) of 3.1&nbsp;&plusmn;&nbsp;1.4&nbsp;mg/mL.</p><p>&nbsp;</p><p>Following a single subcutaneous injection of 100&nbsp;mg, the absorption of golimumab was similar in the upper arm, abdomen, and thigh, with a mean absolute bioavailability of 51%. Since golimumab exhibited approximately dose proportional PK following a subcutaneous administration, the absolute bioavailability of a golimumab 50&nbsp;mg or 200&nbsp;mg dose is expected to be similar.</p><p>&nbsp;</p><p><em>Distribution</em></p><p>Following a single IV administration, the mean volume of distribution was 115&nbsp;&plusmn;&nbsp;19&nbsp;mL/kg.</p><p>&nbsp;</p><p><em>Elimination</em></p><p>The systemic clearance of golimumab was estimated to be 6.9&nbsp;&plusmn;&nbsp;2.0&nbsp;mL/day/kg. Terminal half‑life value was estimated to be approximately 12&nbsp;&plusmn;&nbsp;3&nbsp;days in healthy subjects and similar values were observed in patients with RA, PsA, AS, or UC.</p><p>&nbsp;</p><p>When 50&nbsp;mg golimumab was administered subcutaneously to patients with RA, PsA or AS every 4&nbsp;weeks, serum concentrations reached steady state by week&nbsp;12. With concomitant use of MTX, treatment with 50&nbsp;mg golimumab subcutaneously every 4&nbsp;weeks resulted in a mean (&plusmn;&nbsp;standard deviation) steady‑state trough serum concentration of approximately 0.6&nbsp;&plusmn;&nbsp;0.4&nbsp;mg/mL in RA patients with active RA despite MTX therapy, and approximately 0.5&nbsp;&plusmn;&nbsp;0.4&nbsp;mg/mL in patients with active PsA and approximately 0.8&nbsp;&plusmn;&nbsp;0.4&nbsp;mg/mL in patients with AS. Steady‑state trough mean serum golimumab concentrations in patients with nr‑Axial SpA were similar to those observed in patients with AS following subcutaneous administration of 50&nbsp;mg golimumab every 4&nbsp;weeks.</p><p>&nbsp;</p><p>Patients with RA, PsA or AS who did not receive concomitant MTX had approximately 30% lower steady‑state trough concentrations of golimumab than those who received golimumab with MTX. In a limited number of RA patients treated with subcutaneous golimumab over a 6‑month period, concomitant use of MTX reduced the apparent clearance of golimumab by approximately 36%. However, population pharmacokinetic analysis indicated that concomitant use of NSAIDs, oral corticosteroids or sulfasalazine did not influence the apparent clearance of golimumab.</p><p>&nbsp;</p><p>Following induction doses of 200&nbsp;mg and 100&nbsp;mg golimumab at week&nbsp;0 and 2, respectively, and maintenance doses of 50&nbsp;mg or 100&nbsp;mg golimumab subcutaneously every 4&nbsp;weeks thereafter to patients with UC, serum golimumab concentrations reached steady state approximately 14&nbsp;weeks after the start of therapy. Treatment with 50&nbsp;mg or 100&nbsp;mg golimumab subcutaneous every 4&nbsp;weeks during maintenance resulted in a mean steady-state trough serum concentration of approximately 0.9 &plusmn;&nbsp;0.5&nbsp;mg/mL and 1.8&nbsp;&plusmn;&nbsp;1.1&nbsp;mg/mL, respectively.</p><p>&nbsp;</p><p>In UC patients treated with 50&nbsp;mg or 100&nbsp;mg golimumab subcutaneously every 4&nbsp;weeks, concomitant use of immunomodulators did not have a substantial effect on steady-state trough levels of golimumab.</p><p>&nbsp;</p><p>Patients who developed anti‑golimumab antibodies generally had low trough steady‑state serum concentrations of golimumab (see&nbsp;section&nbsp;5.1).</p><p>&nbsp;</p><p><em>Linearity</em></p><p>Golimumab exhibited approximately dose‑proportional pharmacokinetics in patients with RA over the dose range of 0.1 to 10.0&nbsp;mg/kg following a single intravenous dose. Following a single SC dose in healthy subjects, approximately dose-proportional pharmacokinetics were also observed over a dose range of 50&nbsp;mg to 400&nbsp;mg.</p><p>&nbsp;</p><p><em>Effect of weight on pharmacokinetics</em></p><p>There was a trend toward higher apparent clearance of golimumab with increasing weight (see&nbsp;section&nbsp;4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction and development.</p><p>&nbsp;</p><p>No mutagenicity studies, animal fertility studies nor long‑term carcinogenic studies have been conducted with golimumab.</p><p>&nbsp;</p><p>In a fertility and general reproductive function study in mouse, using an analogous antibody that selectively inhibits the functional activity of mouse TNF&alpha;, the number of pregnant mice was reduced. It is not known whether this finding was due to effects on the males and/or the females. In a developmental toxicity study conducted in mice following administration of the same analogous antibody, and in cynomolgus monkeys using golimumab, there was no indication of maternal toxicity, embryotoxicity or teratogenicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sorbitol(E420)</p><p>L‑histidine</p><p>L‑histidine monohydrochloride monohydrate</p><p>Polysorbate&nbsp;80</p><p>Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>Keep the pre‑filled pen or pre‑filled syringe in the outer carton in order to protect it from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Simponi 100&nbsp;mg solution for injection in pre‑filled pen</u></p><p>1&nbsp;mL solution in a pre‑filled syringe (Type 1&nbsp;glass) with a fixed needle (stainless steel) and a needle cover (rubber containing latex) in a pre‑filled pen. Simponi is available in packs containing 1&nbsp;pre‑filled pen and multipacks containing 3 (3&nbsp;packs of 1) pre‑filled pens.</p><p>&nbsp;</p><p><u>Simponi 100&nbsp;mg solution for injection in pre‑filled syringe</u></p><p>1&nbsp;mL solution in a pre‑filled syringe (Type 1&nbsp;glass) with a fixed needle (stainless steel) and a needle cover (rubber containing latex). Simponi is available in packs containing 1&nbsp;pre‑filled syringe and multipacks containing 3 (3&nbsp;packs of 1) pre‑filled syringes.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Simponi is supplied in a single use pre‑filled pen called SmartJect or as a single use pre‑filled syringe. Each Simponi pack is provided with instructions for use that fully describe the use of the pen or the syringe. After removing the pre‑filled pen or the pre‑filled syringe from the refrigerator it should be allowed to reach room temperature by waiting for 30&nbsp;minutes, before injecting Simponi. The pen or the syringe should not be shaken.</p><p>&nbsp;</p><p>The solution is clear to slightly opalescent, colourless to light yellow and may contain a few small translucent or white particles of protein. This appearance is not unusual for solutions containing protein. Simponi should not be used if the solution is discoloured, cloudy or containing visible foreign particles.</p><p>&nbsp;</p><p>Comprehensive instructions for the preparation and administration of Simponi in a pre‑filled pen or the pre‑filled syringe are given in the package leaflet.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen Biologics B.V.
Einsteinweg 101
2333 CB Leiden
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>